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 INTRODUCTION
Contributors: Tailoi Chan-Ling, Gerard Lutty, Dale Phelps
It only takes a spark to get the fire going and soon all
those around can warm up in its glowing. That is how it was
with this meeting, it started with the simple idea that there
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The Third International Symposium on Retinopathy of Prematurity (ROP) was convened with the aim of cross fertilizing
the horizons of basic and clinical scientists with an interest in the pathogenesis and management of infants with ROP. Ten
speakers in the clinical sciences and ten speakers in the basic sciences were recruited on the basis of their research to
provide state of the art talks. The meeting was held November 9, 2003 immediately prior to the American Academy of
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review contain the summaries of the 20 platform presentations prepared by the authors and the abstracts of presented
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genes, and gene therapy to deliver antiangiogenic agents. The clinical presentations included new insights into oxygen
management, updates on the CRYO-ROP and ETROP studies, visual function in childhood following ROP, the neural
retina in ROP, screening for ROP, management of stage 3 and 4 ROP, ROP in the third world, and the complications of
ROP in adult life. The meeting resulted in a penetrating exchange between clinicians and basic scientists, which provided
great insights for conference attendees. The effect of preterm delivery on the normal cross-talk of neuroretinal and retinal
vascular development is a fertile ground for discovering new understanding of the processes involved both in normal
development and in retinal neovascular disorders. The meeting also suggested promising potential therapeutic interven-
tions on the horizon for ROP.
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exists a need to bring together many of the foremost clinical
and experimental experts in Retinopathy of Prematurity (ROP)
to review and discuss the research frontiers in this field. We
wanted to create an opportunity where clinicians who are faced
with the day to day care of these infants, could enlighten the
scientists about the disease process and highlight unresolved
questions. We also hoped that basic bench scientists could
update the clinicians on the current understanding of the pro-
cesses by which retinal vessels form, during normal develop-
ment and in neovascularization, and to elucidate the latest
therapies that are on the horizon.
We discussed this vision with Dr. Arnall Patz and his en-
couragement to take this idea forward gave us the courage to
make this idea a reality. Dr. Patz took on the role of Honorary
Chair of our Organizing Committee facilitating the smooth
running of every aspect of this meeting with his gentle guid-
ing hand. Drs. John Flynn, Earl Palmer, Bill Tasman and Jan
McColm added further energy to our organizing committee.
However, any scientific meeting is only a success if the scien-
tific program is outstanding. We are indebted to our distin-
guished faculty who accepted our invitation with enthusiasm
and delivered superb elucidation of their assigned topics. Dis-
cussion during the oral and poster sessions was animated, can-
did and penetrating, resulting in the exchange between clini-
cians and basic scientists we had hoped for when planning
this meeting.
The publication of the proceedings from the symposium
will enable our colleagues who were not able to attend the
symposium to benefit from the insights gained at this meet-
ing. The one day symposium consisted of two basic science
sessions and two clinical science sessions. Each speaker has
provided a short summary of their presentation. The session
co-chairs have provided a capstone/commentary at the begin-
ning of each of the four sessions highlighting the importance
of different topic areas, identified areas of controversy, and
have made specific recommendations for future research. The
abstracts from the poster presentations are included in Appen-
dix 1. We wish to thank all the participants of “The 3rd Inter-
national Symposium on Retinopathy of Prematurity: An up-
date on ROP from the Lab to the Nursery” who made this
possible.
 SESSION 1A: EVOLVING BASIC SCIENCE
Contributors: Tailoi Chan-Ling, Maria Grant
While we have made significant progress in our under-
standing of the mechanisms and molecular cues underlying
formation of retinal blood vessels via angiogenesis, the cellu-
lar and molecular cues driving formation of the primordial
vessels via vasculogenesis requires further elucidation (Ses-
sion 1B). The large animal models of kitten and dog mimic
closely the dual role of vasculogenesis and angiogenesis. These
models are similar to what is observed in the formation of
human retinal vasculature and closely mimic the cellular and
vascular changes observed in acute human ROP. The costs of
these larger animal models, the difficulty of access, and the
lack of species-specific antibodies make them less desirable
to use than rodent models (Session 1C).
Mouse models have the additional benefit of transgenic
and knockouts. The mouse and rat models of oxygen-induced
retinopathy (OIR) demonstrate preretinal neovascularization
and have been a major advance to the field. However, there
exists significant strain variability in the angiogenic response
and care must be observed in the selection of genetic back-
ground when conducting studies on the angiogenic response
in rodents (Session 1D). Further, it appears from rodent mod-
els that the ratio of vascular endothelial growth factor (VEGF)/
pigment epithelial derived growth factor (PEDF) determines
OIR susceptibility. This ratio could potentially become a use-
ful measure if studies substantiate that this ratio applies across
all the retinopathies and species.
Recent studies from D’Amore’s lab (Session 1E) have
shown that pericytes and astrocytes express VEGF, that VEGF
expression by pericytes is maintained in adulthood, and that it
plays a role in endothelial signalling (Session 1E). The com-
plex role played by various isoforms of VEGF is beginning to
be unravelled. The most effective intervention for ROP should
minimize the vaso-obliteration/delayed vascularization typi-
fied by phase I of ROP and promote vasculogenesis. Increas-
ing ocular levels of PlGF-1, which specifically activates vas-
cular endothelial growth factor receptors 1 (VEGFR-1), has
been shown to protect against vaso-obliteration in the mouse
OIR model (Session 1F). Increasing serum insulin-like growth
factor 1 (IGF-1) levels towards those observed in utero may
also represent a novel approach to promoting normal
vasculogenesis. However, as pointed out by Smith (Session
1F), even if proven effective, the timing of IGF-1 administra-
tion will require careful determination, as incorrectly-timed
administration could result in a worsening of outcome.
 SESSION 1B: CELL-CELL INTERACTIONS IN THE
FORMATION OF THE HUMAN RETINAL VASCULA-
TURE
Contributors: Tailoi Chan-Ling, Suzanne Hughes
The retina is an extension of the central nervous system.
As such, it consists of 3 main cellular elements: the neurons,
macroglia (including astrocytes and Müller cells), and the vas-
culature (including vascular endothelial cells, pericytes, and
smooth muscle cells). Immune and phagocytic cells including
retinal microglia, macrophages, and perivascular cells com-
plete the cellular milieu. During the formation of the human
retinal vasculature, these cellular elements interact in com-
plex ways resulting in the formation and then the remodeling
of the vasculature to produce a vascular tree that is well
matched to the metabolic needs of the tissue.
Vessels can be formed by two mechanisms, either
vasculogenesis in which vessels are formed from vascular pre-
cursor cells (VPCs) that differentiate and aggregate to form
primitive endothelial tubes or by angiogenesis in which ves-
sels are formed via budding from existing vessels. Formation
of the human retinal vasculature involves both of these pro-
cesses.
The first event in human retinal vascularization, apparent
before 12 weeks gestation (WG), is the migration of large num-
bers of ADPase+/Nissl stained VPCs from the optic disc [1].
©2006 Molecular VisionMolecular Vision 2006; 12:532-80 <http://www.molvis.org/molvis/v12/a63/>
533
These VPCs are also CD39+ (ecto-ADPase) and vascular en-
dothelial growth factor receptor 2 (VEGFR-2) positive [1].
They proliferate and differentiate to form a primordial vascu-
lar bed centered on the optic disc. Thus, vasculogenesis is re-
sponsible for the formation of the primordial vessels of the
inner (superficial) plexus in the central human retina. Angio-
genesis is responsible for formation of the remaining retinal
vessels, including increasing vascular density in the central
retina, vessel formation in the peripheral retina of the inner
plexus, and the formation of the outer (deep) plexus and the
radial peri-papillary capillaries [2]. The fact that the human
retinal vasculature is formed via two distinct mechanisms has
important implications for the understanding of
neovascularization of the human retina.
Formation of the outer plexus begins around the incipient
fovea between 25 and 26 WG [2], coincident with the peak
period of eye opening and the first appearance of the visually
evoked potential, indicative of a functional visual pathway
and photoreceptor activity [3]. The timing and topography of
angiogenesis in the human retina supports the “physiological
hypoxia” model of retinal vascular formation, in which an-
giogenesis is induced by a transient but physiological level of
hypoxia as a result of the increased metabolic activity of reti-
nal neurons as they differentiate and become functional [4-6].
This tissue hypoxia results in upregulation of hypoxia-induc-
ible factor (HIF) 1, resulting in the upregulation of VEGF165
expression [7], by both astrocytes in the inner retina and Müller
cells in the outer retina [8]. The new blood vessels bring oxy-
gen and other metabolic requirements, leading to
downregulation of VEGF165 by neuroglia.
In contrast, formation of retinal vessels via vasculogenesis
appears independent of metabolic demand and hypoxia-in-
duced VEGF165 expression [2]. Evidence for this conclusion
includes three observations. (1) Substantial vascularization in
the human retina occurs prior to detection of VEGF165 mRNA.
At 18 WG, the inner plexus covers approximately 54% of the
retinal area, however, VEGF165 mRNA was not detected in the
human retina by in situ hybridization until 20 WG [9]. (2)
Vasculogenesis is well established by 14 to 15 WG, before the
differentiation of most retinal neurons [10]. (3) The topogra-
phy of formation of the primordial vessels by vasculogenesis
is centered around the optic disc whereas neuronal maturation
is centered around the fovea. The existence of a second path-
way with distinct inhibitory and stimulatory signals could pro-
vide alternative pathways for intervention.
In the human fetal retina, Pax-2 expression is restricted
to cells of the astrocytic lineage [11]. Pax-2 is a member of
the Pax family of transcription factors. Each member of the
Pax family is expressed in a spatially and temporally restricted
manner, which suggests that these proteins contribute to the
control of tissue morphogenesis and pattern formation. Pax-
2+/GFAP- astrocyte precursor cells (APCs) are first evident
at the optic nerve head at 12 WG, preceding the appearance of
Pax-2+/GFAP+ astrocytes. These immature astrocytes are seen
immediately peripheral to the leading edge of vessel forma-
tion (approximately 20-40 µm) and at 18 WG loosely ensheath
the newly formed vessels. With maturation, Pax2+/GFAP+
astrocytes extend towards the periphery, reaching the edge of
the retina around 26 WG [11]. The positioning of the astro-
cytes and APCs just ahead of the leading edge of vessel for-
mation places them in an ideal position to mediate the angio-
genic response to “physiological hypoxia”, via upregulation
of VEGF165 expression [9]. Earlier workers [12-14] have sug-
gested that the spindle shaped, presumed mesenchymal pre-
cursor cells were in fact APCs and not vascular precursors.
Our results show that APCs and VPCs differ in their timing,
topography, and antigenic expression. They thus represent two
distinct populations, supporting the conclusion that formation
of the primordial human retinal vasculature takes place via
vasculogenesis.
Retinal vessels have blood-retinal barrier (BRB) proper-
ties as soon as they become patent. Astrocytes have been shown
to be responsible for inducing the blood-brain barrier proper-
ties in vascular endothelial cells [15] and thus are thought to
induce the blood-retinal barrier in the inner plexus. The pro-
cesses of the Müller cells (the radial glia of the retina) ensheath
the vessels of the outer plexus and are also capable of induc-
tion of the BRB [16].
During normal human retinal vascularization, significant
overproduction of vascular segments occurs and the excess
segments regress with maturation of the vasculature. Our ear-
lier work has shown that endothelial cell apoptosis and mac-
rophages do not initiate vessel retraction, but rather contrib-
ute to the removal of excess vascular endothelial cells through-
out the immature retinal vasculature. Further, our observations
suggest that vessel retraction is mediated by endothelial cell
migration and that endothelial cells derived from retracting
vascular segments are re-deployed in the formation of new
vessels [17]. Mural cells (pericytes and smooth muscle cells)
are an intrinsic part of blood vessel walls with broad func-
tional activities including blood flow regulation and have been
implicated in vessel stabilization [18]. These cells are derived
from a mural precursor cell which gives rise to pericytes on
capillaries and smooth muscle cells on larger vessels [19].
Immature mural cells, the ensheathing mural precursor cells,
in cats, rats and mice, envelop newly formed vessels and have
recently been shown to express VEGF165 [20]. The presence
of these immature mural cells does not prevent vessel regres-
sion during normal development [19] and hyperoxia-induced
vessel regression [21]. As mature vasculatures with mature
mural cells are considered stable, this suggests that mural cell
maturation may be necessary for resistance to VEGF165 with-
drawal-induced vessel regression. Macrophages are also part
of the cellular milieu during formation of retinal vessels [22].
Although their function is unclear they are capable of express-
ing VEGF165 in the mouse model of hyperoxia-induced retin-
opathy [23] and in age-related macular degeneration [24].
The endothelium in turn influences the development of
astrocytes and mural cells. Retinal endothelial cells express
PDGFB which induces recruitment and proliferation of mural
cells [25]. It has also been shown that vascular endothelial
cells can induce astrocyte differentiation [26,27]. In addition,
contact between mesenchymal precursor cells and vascular
endothelial cells leads to mural cell differentiation in vitro [28].
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Figure 1. Cell-cell interactions in developing retina.  Schematic representation of the complex cell-cell interactions during formation of human
retinal vasculature showing how neurons, astrocytes, and pericytes all play a role in influencing the formation of blood vessels. For each class
of cells and the vasculature, maturation along the differentiation pathway is shown from left to right. The proposed molecular intercellular
signals where known are shown with their functional interactions. All data shown are from human retina with the exception of pericytes which
are from rat retina.
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Taken together, these studies show that the formation and matu-
ration of the human retinal vasculature is (1) concurrent with
neuronal, astrocyte and mural cell differentiation and matura-
tion, as represented schematically in Figure 1, and (2) the re-
sult of complex cellular interactions in which the vasculature
both takes its developmental cues from, and also influences
its cellular environment. During normal development, the reti-
nal vasculature is remodeled resulting in a vascular pattern
that is well matched to the metabolic demands of the tissue.
Thus, the overriding drive of the retina, to meet its ever chang-
ing metabolic needs, results in the reactivation of angiogenic
signals, where vascular perfusion has been compromised re-
sulting in retinal neovascularization.
 SESSION 1C: LARGE ANIMAL MODELS OF ROP
Contributors: Gerard Lutty, D. Scott McLeod
Two large laboratory animals have been used for experi-
mental models of ROP, the cat and dog. In both species, the
neonatal animals were exposed to high oxygen for short peri-
ods, modeling the vaso-obliterative stage of ROP. When the
animals are returned to room air, the retinas are hypoxic and
angiogenesis occurs.
Cat model: The cat was used first by Norman Ashton et
al. [28] in 1954. He evaluated the effects of different levels of
oxygen and duration of exposure and found that the longer
the exposure and the greater the concentration of oxygen, the
more severe the retinopathy. Arnall Patz at first used the cat
model that Ashton had developed as he explored the effects of
hyperoxia on the developing retinal vasculature in several spe-
cies [29]. He later, in collaboration with Robert Flower, was
able to view the effects of hyperoxia on the cat retinal vascu-
lature in situ [30,31]. Dale Phelps also used the cat model in
her pioneering studies on the effects of vitamin E on the oxy-
gen induced vaso-obliteration [32] and later in her studies of
oxygen withdrawal protocols which led to the STOP-ROP
clinical trial [33]. More recently, Tailoi Chan-Ling et al. [6]
have utilized the kitten model to elucidate the vascular and
cellular changes that underlie the various stages of the human
disease [6,8,34-36] and have also used the cat model to dem-
onstrate the concept of “physiological hypoxia,” which Patz
[37] and Ashton [28] had hypothesized earlier from their ex-
perimental studies of ROP in cat.
Phelps and Chan-Ling expose 0- to 3-day-old kittens to
80% oxygen for 80-96 h [33,34]. This results in obliteration
of more than 80% of the retinal vasculature. The longer the
exposure to this concentration of oxygen, the more severe the
vaso-obliteration and vasoproliferation will be [38] and by 10
days after return to room air, significant preretinal vascular
membranes are evident [34]. Tailoi Chan-Ling has demon-
strated astrocyte death during the hypoxia after reintroduc-
tion to room air and that recovery of the blood-retinal barrier
in the kitten model of ROP is coincident with ensheathment
of the retinal blood vessels by astrocytes [35]. The reforming,
retinal vasculature was described by Chan-Ling et al. [34] as
a rosette-like vasculature and she demonstrated that it leaked
profusely using horse radish peroxidase as a vascular tracer.
By day 14, tufts of neovascularization appear throughout the
fundus and large networks can exist around or near the optic
nerve head. Ashton demonstrated that the small tufts were
glomeruloid-like neovascular formations, which appeared
similar to angioblastic masses with few canalized lumens [28].
These tufts are called “popcorn” formations by some clini-
cians. Eventually the neovascularization matures and spreads
through vitreous across the surface of the retina. The Phelps
and Chan-Ling labs have both demonstrated that VEGF
upregulation is associated with the vasoproliferative phase of
OIR in the cat [38,39]. Importantly, Chan-Ling et al. [36] have
shown that it is possible with supplemental oxygen to
revascularize a kitten retina with minimal astrocyte degenera-
tion and breakdown of the blood retinal barrier. This results in
a vascular tree showing lobular topography and morphology
seen during normal development, lending support to the im-
portance of tight oxygen administration to produce optimized
vascular formation.
The dog model: The canine model of OIR was first used
by Arnall Patz in 1954 [40]. Robert Flower used this model in
the 1970s and investigated the effects of prostaglandin inhibi-
tors on severity of retinopathy [41]. Scott McLeod and I have
carefully documented each stage in the disease process more
recently using adenosine diphosphatase (ADPase) enzyme
histochemistry and used the model to evaluate antiangiogenic
therapies.
One reason that we prefer this model is that the initial
retinal blood vessel assemblage in the neonatal dog occurs
primarily by a process of vasculogenesis [42,43], a term re-
ferring to de novo formation of vasculature from mesenchy-
mal precursors or angioblasts. We have recently described this
same process using ADPase enzyme histochemistry in the fe-
tal human retina (Session 1B). During development, the inner
Müller cell processes form a network of interconnecting ex-
tracellular spaces, which furnish a scaffold for angioblast at-
tachment and organization during blood vessel assemblage and
provide unimpeded growth anteriorly [43]. In the dog, astro-
cyte migration, as assessed with glial fibrillary acidic protein
(GFAP) immunolabeling, lags behind formation of the pri-
mary retinal blood vessels [44]; while in cat [45], GFAP+ as-
trocytes precede the formation of a patent vasculature by a
small margin.
Sustained breathing of 100% oxygen for four days pro-
duces a progressive constriction of the developing retinal vas-
culature that eventually results in vaso-obliteration, or the ir-
reversible closure of many capillary channels and subsequent
death of capillaries from optic nerve head to the edge of the
forming vasculature. In cross sections, pericytes can be seen
on collagenous tubes, suggesting they survive hyperoxia while
endothelial cells die. The end product of vaso-obliteration in
the neonatal dog model of ROP is a 77% reduction in capil-
lary density and a 60% decrease in lumenal diameter of re-
maining viable retinal capillaries (Figure 2A,B). There are
often surviving islands of ADPase positive endothelial cells.
In contrast, the choriocapillaris appears unaffected morpho-
logically by prolonged oxygen breathing [46].
In the dog, revascularization following hyperoxic insult
involves a period of marked vasoproliferation that peaks some-
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where between three to ten days after return to room air [44].
In addition to the marked increase in endothelial cell prolif-
eration, there is proliferation of perivascular cells, presum-
ably astrocytes. Hyperoxic insult, followed by return to room
air, not only stimulates a marked increase in proliferation of
vasoformative cells and apparent accessory glia, but also re-
sults in a loss of extracellular spaces, which were prevalent in
the inner retina during the course of normal development. The
diminution of spaces in the peripheral avascular retina after
return to room air and the occupancy of these spaces by cells
not normally found in advance of forming blood vessels is
likely to impede vascular growth anteriorly. As many as six
layers of capillaries form in the nerve fiber layer during the
vasoproliferative stage. Marked vasoproliferation in the ab-
normal confines of this congested perivascular milieu prob-
ably contributes to the prolific capillary overgrowth at the
anterior edge of reforming vasculature and to the invasion of
vessels into the vitreous cavity. The initial formations are im-
mature, angioblastic masses with very few formed lumens,
similar to what Ashton observed in the cat [47]. When these
formations mature, they develop a 1:1 ratio of endothelial
cells:pericytes in these blood vessels [47]. Enzyme histochem-
istry demonstrated high alpha glycerophosphate dehydroge-
nase activity, a marker for angioblasts and immature endothe-
lial cells, in poorly differentiated neovascular formations and
low activity in formations with mature pericytes and endothe-
lial cells.
Fifteen days after exposure to hyperoxia, fluorescein an-
giography and funduscopic examination can be performed on
the dogs. From this time in the disease process, ADPase flat-
embedded retinas demonstrate dilated and tortuous retinal ves-
sels, pigmentary changes, incomplete vascularization of pe-
ripheral retina, vitreous hemorrhage, and large intravitreal
neovascular formations (Figure 2C,D) [48]. The small
neovascular formations seem to fuse with time, and this syn-
cytium creates large mats of neovascularization that often fol-
lows the vascular arcades (Figure 2E,F). Full thickness eyewall
sections at 22 days and later demonstrated tractional retinal
folds, tented intravitreal vascularized membranes and vitre-
ous synchysis. GFAP immunohistochemical analysis revealed
inner retinal astrogliosis at the edge of the reforming vascula-
ture. End stage OIR in the neonatal dog shares many features
with the chronic human disease. The tented membranes and
tractional retinal folds persist at least until 45 days of age, the
longest time we have to date.
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Figure 2. Canine model of oxygen-induced retinopathy.  A: ADPase whole mount showing the temporal arcade of a 5-day-old normal air
control dog (the arrow indicates an artery). Note the density and chicken wire mesh appearance of the developing capillaries. B: ADPase
whole mount showing the temporal arcade of a 5-day-old dog sacrificed after 4 days of 100% oxygen exposure (the arrow indicates an artery).
Note the obliteration of the capillaries and the extreme constriction of the major vessels. C: ADPase whole mount showing the temporal arcade
of a 21-day-old normal air control dog (the arrow indicates an artery). Capillary-free zones have formed along the arteries and remodelling of
the capillary bed has occurred. The secondary capillary bed has also formed. D: ADPase whole mount showing the temporal arcade of a 21-
day-old oxygen-treated dog after return to room air for 16 days. The arteries are extremely tortuous (arrow) and an overgrowth of the capillar-
ies is apparent. E: Fundus photograph of a 45-day-old oxygen-treated dog. Preretinal membranes extend along the major arcades and over the
optic nerve head (arrow). F: Histological section from the animal shown in Panel E, shows tractional retinal folds (arrowheads) associated
with the preretinal membrane (arrow).          
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Figure 3. Strain-dependent corneal angiogenesis.  A: Corneas were
photographed 7 days after implantation of a hydron polymer pellet
containing 75 ng of basic fibroblast growth factor (bFGF) into a cen-
tral corneal micropocket. B: Resting limbal vascularity was strain
dependent. Photographs of the limbal vessels were taken in normal,
unoperated, adult eyes. C: Limbal vessel density differences between
mouse strains were further evaluated by fluorescence microscopy
after labeling with endothelial-specific fluorescein conjugated
Griffonia simplicifolia lectin. Republished with permission of The
Association for Research in Vision & Ophthalmology from Chan
CK, Pham LN, Chinn C, Spee C, Ryan SJ, Akhurst RJ, Hinton DR.
Mouse strain-dependent heterogeneity of resting limbal vasculature.
Invest Ophthalmol Vis Sci 2004; 45:441-7.
In both cat and dog, VEGF has been implicated as a stimu-
lus for the angiogenic process when the animals are returned
to room air and the retina is hypoxic. We have also demon-
strated a close association between adenosine, the develop-
ment of the retinal vasculature, and the angiogenic process in
the dog OIR model [49]. Adenosine A2a receptors are associ-
ated with angioblasts and endothelial cells in intraretinal and
intravitreal neovascularization [44]. The source of the adenos-
ine appears to be the enzyme 5' nucleotidase in the inner Müller
cell processes [50].
The usefulness of the canine model is exemplified in a
study that examined the effects of neutralizing KDR (VEGF
receptor 2) on vasculogenesis and angiogenesis in OIR [51].
The binding of a humanized chimeric neutralizing antibody
in dog retina and choroid was done with immunohistochemis-
try. KDR immunoreactivity was only weakly associated with
developing retinal vessels and not observed in angioblasts
throughout normal postnatal development. Immunoreactivity
was very strong in reforming retinal vessels and intravitreal
neovascularization in oxygen-treated animals. To examine the
effects of blocking KDR, 6-day-old air control and oxygen-
treated animals were surgically implanted with Elvax pellets
containing control IgG or anti-KDR. Anti-KDR had no effect
on vessel morphology or growth in air control animals at 22
days of age using ADPase histochemistry. In oxygen-treated
animals, anti-KDR significantly inhibited revascularization of
the retina and formation of intravitreal neovascularization com-
pared to control IgG pellet eyes. Therefore, blocking KDR
affected proliferation of endothelial cells in the formation of
intravitreal neovascularization and revascularization of retina
in OIR but did not have an effect on normal development of
the primary retinal vessels, which occurs by vasculogenesis
and not by proliferation of endothelial cells. The study sug-
gests that blocking KDR might be beneficial for treating patho-
logic angiogenesis in adult tissue but caution must be used in
preventing revascularization of the retina in OIR.
Benefits of large animal models of ROP:  Both the dog
and cat models of OIR have robust neovascularization with
pathological features similar to human ROP. The
neovascularization is prolonged in both species lasting at least
45 days in dog and longer in cat. The dog neovascular forma-
tions are not only long lived but also eventually cause trac-
tional retinal folds in retina like human ROP. The vitreous
cavity in both species is large enough that bioerodable poly-
mers with antiangiogenic agents could be evaluated. There-
fore, these models can be used for preclinical evaluation of
therapeutic antiangiogenic agents. The optimal therapy prob-
ably should target only preretinal neovascularization.
Question by John Flynn: Why is cat and dog oxygen-
induced retinopathy so severe compared to rodents?
Response: The vaso-obliteration is more severe in the large
animals, so perhaps that results in greater neovascularization,
which persists longer. The dog has some very mature
neovascular formations (1:1 ratio of pericytes to endothelial
cells) that may contribute to the longevity. Alternatively, there
may be a balance of angiogenic and antiangiogenic factors in
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the rodents that favors regression of NV not persistence or
maintenance of the neovascular formations.
SESSION 1D: GENOMIC VARIATION AND SUSCEPTI-
BILITY IN RODENT MODELS OF OXYGEN-INDUCED
RETINOPATHY
Contributors: John Penn, Candy K. Chan, David R. Hinton
From their use in the very first investigations of the patho-
genesis of the condition, rodent models have remained the
mainstay of ROP research. They were integral to the studies
of Patz [52], Ashton [28], and Gyllensten and Hellstrom [53]
who first defined the correlation between oxygen therapy and
ROP pathology, and they continue to play important roles in
the current studies that further refine our thinking. Widely used
rat and mouse models of ROP have been developed [54,55],
and each has its clear advantages. We will leave it to the reader
to examine the published methods by which the animals are
induced to produce ROP-like pathology and techniques with
which the pathology is measured. Briefly, the critical patho-
logic feature of the widely adopted rodent models of Penn
and Smith [54,55] is preretinal neovascularization (NV). The
preretinal vessels are stained and quantified in transverse reti-
nal sections or in whole-mount retinal preparations. In animal
models, the term OIR is most often used to distinguish the
condition from human ROP. This general approach was used
in most of the studies described below.
In addition to their important role in ROP research, rat
and mouse models of OIR have been employed by investiga-
tors in other disciplines to define the molecular and cellular
basis of angiogenesis for application to tumor growth, non-
ocular diabetic complications, wound healing, and heart dis-
ease, among others. In addition, rodent models of OIR are the
cornerstones of pre-clinical efficacy trials for angiostatic agents
under development for any number of ocular and non-ocular
conditions. The prominent role of rodents in these endeavors
relies on a number of beneficial features of OIR models in-
cluding: rodents have relatively large litter sizes, they are in-
expensive to purchase and maintain, the models have been
extensively characterized, and they have proven reliable in
producing NV under appropriate conditions.
Another advantageous feature of rodents lies in the ease
of defining and comparing genetic differences among various
inbred strains or differences between isolated colonies of the
same strain. Segregation of genomic content yields rodents
with different gene expression profiles and different suscepti-
bilities to disease. This allows for the identification of gene
products that influence angiogenesis susceptibility, providing
candidate therapeutic targets. The rationale of the target can
be confirmed by further manipulating gene expression using
transgenic technology, a process that is particularly facile in
mice.
This experimental strategy was foreshadowed by a few
anecdotal findings. The first of these (Penn, unpublished ob-
servations) was not a comparison of strains, per se, but was a
comparison of the pathologic response of one rat strain ob-
tained from four different vendors. Pregnant Sprague-Dawley
rats were obtained from Charles River, Hilltop, Harlan, and
Zivic. The litters were exposed to the 50/10% variable oxy-
gen paradigm developed by Penn et al. [56]. This exercise
yielded a greater than two fold difference in susceptibility to
retinopathy as measured by the area of retinal NV. Charles
River rats produced 3.0 mm2 NV area, while rats obtained
from Zivic produced only 1.2 mm2. Rats from the other two
suppliers yielded intermediate levels of pathology. At the time,
we postulated that a genomic drift in these isolated and inbred
colonies of rats had produced this difference in susceptibility.
In 2002, Holmes et al. [57] conducted a similar experi-
ment. Their results supported the difference in susceptibility
to OIR of rats from two different vendors, in this case Charles
River and Harlan. However, the difference did not hold for
retinopathy produced by metabolic acidosis [58]. The data
showed a 62% increase in the susceptibility of Charles River
over that of Harlan-bred animals in the induction of NV by
oxygen. Their induction of NV by metabolic acidosis yielded
a statistically insignificant difference of only 14%. This sug-
gests that the OIR susceptibility differences between strains
are potentially dependent on the mechanism by which the an-
giogenesis is initiated, further implying that upstream events
in the angiogenesis cascade warrant special attention.
The most systematic comparison of strains to date comes
from D’Amato et al. [59]. The authors used the corneal mi-
cro-pocket assay to evaluate the growth of blood vessels from
the limbal area into the normally avascular cornea under the
influence of basic fibroblast growth factor (bFGF), an angio-
genic protein. D’Amato compared 25 strains of mice for sus-
ceptibility to corneal NV. When 80 ng of bFGF was implanted
in the corneal pocket, C57BL/6J mice fell near the middle of
the susceptibility profile, while 129/SvImJ strains were sig-
nificantly more susceptible and other strains were less than
half as susceptible. Evaluation of F1 and F2 hybrid animals,
created by crossing strains of low and high angiogenic poten-
tial, suggested that angiogenic potential is genetically deter-
mined and that multiple genes are involved. When the corneal
pocket assay was modified, using VEGF as the angiogenic
agent instead of bFGF, they found that variability in VEGF
responsiveness also varied among mouse strains and that it
correlated with results found for bFGF [60]. Subsequently,
D’Amato et al. [59-61] mapped quantitative trait loci (QTL)
associated with bFGF and VEGF responsiveness in recombi-
nant inbred mouse strains and found that these regions con-
tain a number of genes known to be involved in angiogenesis
[60,61]. It is hoped that further work evaluating these genetic
regions will identify functional polymorphisms in genes con-
tributing to the angiogenic response.
Recently, Chan et al. [62] similarly reported that there
was a wide range in bFGF-induced angiogenic responses
among inbred mouse strains using the corneal micropocket
assay (Figure 3). They considered the possibility that these
responses may, in part, be due to differences in the resting
limbic vasculature from which the angiogenic corneal vessels
are derived. Interestingly, they found that there was a similar
wide range in resting limbic vessel vascular density suggest-
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ing the possibility that genetic factors controlling the devel-
opment of the limbic vasculature may also play a role in their
angiogenic response (Figure 3) [62].
In 2002, Ma [63] conducted an experiment comparing
Brown Norway and Sprague-Dawley rat strains using a con-
stant oxygen exposure paradigm like that developed by Smith
et al. [55] for mice. The avascular area at the time of removal
of the rats from oxygen was eight fold greater in the more
susceptible Brown Norway rats than in the Sprague-Dawley
rats. This avascular retina provides the impetus for subsequent
NV. Consequently, after the post-exposure room air period,
the Brown Norway rats exhibited a three fold greater degree
of NV. Ma extended the study to look at retinal factors that
had the potential to produce this difference in susceptibility.
He focused on VEGF and PEDF, calculating ratios of the reti-
nal levels of these two factors at various times during the after
exposure period for the two strains of rats. VEGF, an endog-
enous endothelial cell-specific mitogen, is widely recognized
as the driving force behind retinal NV in ROP, while PEDF is
the most potent endogenous inhibitor of angiogenesis identi-
fied to date. Ma’s findings are best summarized by focusing
on the P16 time (4 days post-exposure to hyperoxia). Here,
the ratio of VEGF to PEDF was ten fold greater in the more
susceptible Brown Norway rats, a circumstance that would
presumably be permissible for NV.
Recently, Berkowitz et al. confirmed the work of Ma, dem-
onstrating that Sprague-Dawley and Brown Norway rats dif-
fered significantly in their susceptibilities to constant OIR,
with the latter strain showing a seven fold greater degree of
NV (Berkowitz, personal communication to John Penn). In
addition, Berkowitz employed variable oxygen exposures and
these treatments, surprisingly, yielded no difference in sus-
ceptibility. The VEGF to PEDF ratios were not measured, but
based upon Ma’s work, correlation of this ratio to OIR sus-
ceptibility in these sets of conditions is warranted.
Hinton’s group has presented preliminary data evaluat-
ing mouse strain-related differences in susceptibility to OIR
[64]. They found that both preretinal and intraretinal NV var-
ied among inbred mouse strains with 129S3/SvIM mice show-
ing significantly more NV than the C57BL/6J strain. They are
currently using this model to evaluate the level of mRNA and
protein expression for several pro-angiogenic and anti-angio-
genic genes at various times in both of these strains. Prelimi-
nary results suggest that the ratio of VEGF/PEDF is higher in
the more angiogenic 129S3/SvIM strain.
Collectively, these studies present an intriguing mix of
findings. Particularly interesting is the tight correlation be-
tween the VEGF to PEDF ratio and OIR susceptibility. The
work of Ma and Hinton points to a prominent role for these
factors and emphasizes the need to assay them in the combi-
nations of treatment or strain (vendor comparison, metabolic
acidosis compared to OIR comparison and variable compared
to constant OIR comparison) used by other investigators. Cer-
tainly other factors besides VEGF and PEDF participate in
the regulation of ROP angiogenesis, but if these various sets
of experimental conditions all yield the appropriate pattern of
VEGF:PDEF ratios, a compelling argument can be made for
the controlling influence of these two factors (Figure 4). The
next critical question will become whether the ratio is predic-
tive for disease severity.
Systematic studies designed to correlate gene expression
and pathology susceptibility are still in their infancy, yet their
value to the study of ROP is already evidenced by these inves-
tigations. With today’s advances in gene microarray technol-
ogy, comparison of the complete genomes of rats and mice
exposed to various experimental conditions is possible. This
certainly will yield a myriad of new targets for investigation,
and initially this will complicate the process of defining the
most influential factors. Ultimately, however, it will lead us to
novel therapeutic targets that may provide relief for infants at
risk for ROP.
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Figure 4. Mechanisms of strain-de-
pendent angiogenesis.  Schematic
diagram illustrating mechanisms of
strain-dependent angiogenesis. The
molecular equilibrium between pro-
angiogenic and anti-angiogenic
growth factors may play a role in
establishing mouse strain-dependent
differences in resting vascular den-
sity and surface area, and the extent
of responses to angiogenic stimuli.
We speculate that such differences
may also be predictive of suscepti-
bility to angiogenesis-dependent
diseases. The growth factors of in-
terest are basic fibroblast growth
factor (bFGF), vascular endothelial
growth factor (VEGF), pigment epi-
thelium derived growth factor
(PEDF).
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Figure 5. VEGF and its isoforms in reti-
nal development, oxygen-induced retin-
opathy, and adult retinal vasculature.  A:
Mouse model of retinal vascularization
and ROP (adapted from Stone et al. [8]).
During normal retinal development (left
side of panel A), maturation of the neu-
ral retina induces a “physiologic hy-
poxia” anterior to the growing vessel tips.
Astrocytes spreading from the optic nerve
to the periphery respond to the hypoxia
by expressing vascular endothelial
growth factor (VEGF), which in turn pro-
motes the formation of the superficial
vascular network. Subsequently, a second
wave of neuronal activation induces
VEGF secretion in the inner nuclear
layer, leading to the formation of the deep
vascular layers of the retina. Once the tis-
sue is vascularized, VEGF expression
decreases and the new vessels are remod-
eled and stabilized. Under hyperoxic con-
ditions (drawings to the right), VEGF ex-
pression is downregulated before the
completion of the normal vascular devel-
opment, leading to the obliteration of the
central retinal vessels. Once returned to
normoxia, the unperfused tissue becomes
highly hypoxic, inducing a strong and un-
controlled secretion of VEGF and the
formation of vascular buds invading the
vitreous, characteristic of the pathologi-
cal neovascularization. B: Localization of
VEGF in developing and adult retinal
vasculature. Retinas from P9.5 and 6
months old VEGF-lacZ+/- mice were co-
stained for βgal expression in combina-
tion with astrocytes and endothelial cell-
associated proteins (GFAP and PECAM,
respectively). Numerous βgal-positive
nuclei, reflecting VEGF expression, can
be observed in both developing and ma-
ture retina. βgal-positive nuclei are not
all co-localized with GFAP staining,
some are characteristically associated
with the vessels in a pattern characteris-
tic of pericytes, indicating pericytes pro-
ducing VEGF. C: Quantification of
VEGF mRNA isoforms levels in adult
mouse organs using RNase protection
assay. The height of the columns repre-
sent the levels of total VEGF mRNA, and
the relative levels of different VEGF
isoforms are indicated in the divisions.
Both level of total VEGF mRNA and relative VEGF isoforms expression varies among tissues. A: Republished with permission of the
University of the Basque Country Press from Saint-Geniez M, D’Amore PA. Development and pathology of the hyaloid, choroidal and retinal
vasculature. Int J Dev Biol 2004; 48:1045-58. B: Republished with permission of Elsevier from Darland DC, Massingham LJ, Smith SR, Piek
E, Saint-Geniez M, D’Amore PA. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial
survival. Dev Biol 2003; 264:275-88. C: Republished with permission of Wiley-Liss, Inc., a subsidiary of John Wiley and Sons, Inc., from Ng
YS, Rohan R, Sunday ME, Demello DE, D’Amore PA. Differential expression of VEGF isoforms in mouse during development and in the
adult. Dev Dyn 2001; 220:112-21.
A:
B:
C:
541
SESSION 1E: REVISITING THE ROLE OF VEGF IN
ROP
Contributors: Magali Saint-Geniez, Patricia D’Amore
A role for VEGF in the pathogenesis of ROP has been
clearly established. In the human [11], cat [45], rat [65] and
mouse retina [66], astrocytes migrate into the developing retina
in front of the forming vasculature. A “physiologic hypoxia”
develops, due to the increased metabolic demands of the dif-
ferentiating neural retina, leading to upregulation of astrocyte
VEGF production [6,39]. The gradient of VEGF produced
mediates continued vascularization of the ganglion cell layer.
Synthesis of VEGF by the Müller cells, also stimulated by a
local oxygen deficit, induces the sprouting of the vasculature
downward into the inner nuclear layer. Once metabolic de-
mands are met, hypoxia subsides and VEGF expression de-
clines (Figure 5A).
It is hypothesized that when premature infants are placed
in high oxygen, the “physiologic hypoxia” signal is overrid-
den and astrocyte VEGF synthesis is suppressed [67]. The lack
of VEGF leads to the regression of immature vessels (vaso-
obliteration), which during their development are dependent
on exogenous VEGF for their continued survival. Once the
infant is returned to room air, nonperfused retina becomes is-
chemic and the hypoxic environment upregulated VEGF syn-
thesis in astrocytes and other neural cells. The “global” nature
of the VEGF production by a significant area of nonperfused
retina, compared to the local release by a limited number of
astrocytes, leads to uncontrolled, abnormal vessel growth (Fig-
ure 5A).
Thus, the dogma has developed that VEGF expression
virtually ceases once the retina is vascularized and normoxic.
Recent observations from our lab reveal that there is constitu-
tive VEGF expression in the adult retina by both astrocytes
and some pericytes [20]. Using VEGF lacZ mice [68], we have
shown that VEGF expression is maintained in adult retina.
Confocal analysis of adult retina revealed the presence of nu-
merous βgal-positive nuclei characteristically associated with
the vessels. Presumably, the pericytes were positive (Figure
5B), since pericyte differentiation is associated with an induc-
tion of VEGF [20]. This expression of VEGF in adult tissue is
not specific to the retina alone. In fact, a survey of adult mu-
rine tissues for the expression of VEGF reveals that virtually
all adult tissues examined to date express VEGF, albeit at dif-
ferent levels (Figure 5C) [69]. The relative expression of the
different VEGF isoforms varies among different tissues and
organs. For example, while most tissues have relatively little
VEGF188, in lung and heart more than 50% of the VEGF was
VEGF188 (Figure 5C). Evidence of the functional significance
for the differential isoform expression has been supplied by
mice that express single VEGF isoforms. Thus, mice that ex-
press only VEGF120 (and lack VEGF164 and VEGF188) develop
to term (at reduced Mendelian ratios) and die within hours
after birth from defects in cardiac and pulmonary develop-
ment [70,71]. Similarly, mice expressing only VEGF120 had
impaired retinal vascularization and patterning; mice express-
ing only VEGF188 displayed normal development of venous
circulation but defective arterial development [72]. As VEGF
isoforms do not share the same function in regulating vascu-
lar formation and remodeling, they could also contribute dif-
ferentially in the progression of pathological
neovascularization. Recently, Ishida et al. [73] confirmed this
hypothesis showing that VEGF164 inhibition can suppress
pathological neovascularization without affecting physiologi-
cal angiogenesis in the rat model of ROP.
The constitutive expression of VEGF in adult tissues leads
to the question of what role VEGF plays in a tissue, in the
absence of active angiogenesis. We have speculated that VEGF
in the adult plays a role in stabilization of the microvascula-
ture. These functions have been addressed to some extent in
experimental models. Acute withdrawal of VEGF from newly
formed vessels, such as occurs in the ROP model [67] or in
experimental tumors systems [74], leads to the regression of
the nascent vessels. VEGF is also suspected to play a role in
the differentiation of the endothelium; addition of VEGF to
endothelial monolayers leads to the formation of fenestrations,
a microvascular specialization [75].
The role played by VEGF in stable, mature vessels has
not been elucidated. Observations from our lab and others of
highly specific expression patterns of VEGF [69] and its re-
ceptors [76] in combination with evidence that VEGFR-2 is
constitutively activated in the retina (Saint Geniez and
D’Amore, unpublished data) [77] strongly indicate that the
VEGF produced by pericytes in the adult retinal microvascu-
lature is signaling to the endothelium. A variety of studies are
currently underway to block VEGFR-2 signaling and should
allow us to determine if, in fact, this signaling is biologically
relevant in terms of vessel survival and stabilization.
SESSION 1F: CAN WE PREVENT ROP THROUGH
MANIPULATION OF VEGF AND IGF-1?
Contributors: Lois Smith
ROP is a major cause of blindness in children despite
current treatment of stage 3 ROP. As neonatal care in devel-
oping countries improves, the incidence of ROP increases.
Preventive therapy would be of great benefit.
ROP was first described by Terry in the 1940s and asso-
ciated shortly thereafter with excessive oxygen use [78].
Supplemental oxygen is now monitored carefully. Even with
controlled oxygen use, the number of infants with ROP has
increased further [79] due to the increased survival of very
low birth weight infants [80].
Pathogenesis: Two phases of ROP: Infants born prema-
turely have incompletely vascularized retinas, with a periph-
eral avascular zone. The normal retinal vascular growth, which
would occur in utero ceases, and there is loss of some of the
developed vessels, this represents phase I of ROP. With matu-
ration of the infant, the nonvascularized retina becomes in-
creasingly metabolically active and increasingly hypoxic.
Retinal neovascularization characterizes Phase II of ROP. It is
hypoxia-induced and typically begins at 32-34 weeks post-
menstrual age. Mice, rats, cats, and dogs, though born full
term, have eyes that are incompletely vascularized at birth and
resemble the retinal vascular development of premature in-
fants. Exposure of these neonatal animals to hyperoxia causes
©2006 Molecular VisionMolecular Vision 2006; 12:532-80 <http://www.molvis.org/molvis/v12/a63/>
542
loss of vessels and cessation of normal retinal blood vessel
development; this mimics phase I of ROP [28,46,55,81]. Upon
return to room air, the nonperfused portions of the retina be-
come hypoxic, which in turn causes retinal neovascularization,
similar to phase II of ROP and other retinopathies.
VEGF and phase II of ROP: Phase II of ROP is driven by
hypoxia. VEGF is a hypoxia-inducible cytokine. In the mouse
and kitten models of ROP, there is a temporal relationship
between VEGF and proliferative retinopathy; retinal hypoxia
stimulates an increase in the expression of VEGF before the
development of neovascularization [39,55,82]. Inhibition of
VEGF decreases the neovascular response [83,84] indicating
that VEGF is a critical factor in retinal neovascularization.
The central role of VEGF in ocular neovascularization has
also been demonstrated by other investigators in other animal
models [38,39,85-87] and correspond to clinical observations.
VEGF is elevated in the vitreous of patients with retinal
neovascularization [88,89]. VEGF was found in the retina of
a patient with ROP in a pattern similar to that observed in
mouse studies [85].
VEGF and phase I of ROP: Normal blood vessel growth
is also VEGF dependent. In phase I, hyperoxia suppresses
normal VEGF driven vessel growth. Blood vessels grow from
the optic nerve to the periphery. As neural retina develops an-
terior to the vasculature there is increased oxygen demand,
which creates localized physiologic hypoxia, an increase in
VEGF, and blood vessels grow toward the stimulus [8,90]. As
the hypoxia is relieved by oxygen from the newly formed ves-
sels, VEGF mRNA expression is suppressed, moving the wave
forward.
Supplemental oxygen interferes with normal VEGF-
driven vascular development [6]. Furthermore, hyperoxia-in-
duced vaso-obliteration is caused by apoptosis of vascular en-
dothelial cells. Vaso-obliteration can be partially prevented
by administration of exogenous VEGF, or in particular by ad-
ministration of placental growth factor (PlGF-1), the ligand
specific to VEGFR-1 [67,90,91]. Thus VEGFR-1 is required
for vessel survival. This indicates that VEGF acting through
VEGFR-1 is required for maintenance of the immature retinal
vasculature and explains, at least in part, the effect of hyperoxia
on normal vessel development in ROP.
Although hyperoxia alone can cause cessation of vascu-
lar growth and vaso-obliteration in animal models, it is clear
that clinical ROP is multifactorial. Despite controlled use of
supplemental oxygen, the disease persists as ever more im-
mature infants are saved, suggesting that other factors related
to prematurity itself are also at work.
Growth hormone and insulin-like growth factor in phase
II of ROP: Prematurity is the most significant risk factor for
ROP. Because growth hormone has been implicated in prolif-
erative diabetic retinopathy, we considered growth hormone
(GH) and IGF-1 the mediator of many of GH’s mitogenic ef-
fects, as potential candidates in ROP.
Proliferative retinopathy, the second phase of ROP [92],
is substantially reduced in transgenic mice expressing a growth
hormone receptor antagonist, in normal mice treated with a
somatostatin analog that decreases growth hormone release,
or in mice treated with an IGF-1 receptor antagonist.
IGF-1 may not act through VEGF under physiological
conditions [92,93]. However, it appears that IGF-1 can act
permissively to facilitate maximum VEGF stimulation of new
vessel growth as VEGF alone may not be sufficient for pro-
moting vigorous retinal angiogenesis.
IGF-1 and phase I of ROP: Similar to the role of VEGF
in both phases of ROP, IGF-1 is critical to phase I [94]. The
extent of phase II of ROP is determined by the extent of phase
I. IGF-1 levels fall from in utero levels after birth, due to the
loss of IGF-1 provided by the placenta and the amniotic fluid.
We hypothesized that IGF-1 is critical to normal retinal vas-
cular development and that a lack of IGF-1 in the early neona-
tal period is associated with lack of vascular growth and sub-
sequent proliferative ROP. In IGF-1 knockout mice retinal
blood vessels grow more slowly than in those of normal mice,
a pattern very similar to that seen in premature babies with
ROP. We found that IGF-1 controls maximum VEGF activa-
tion of the Akt endothelial cell survival pathway. These obser-
vations were confirmed in patients with ROP [94,95].
In 84 premature infants, the mean IGF-1 level was sig-
nificantly and proportionately lower in post-menstrual-age-
matched babies with each stage of ROP than without ROP.
These finding suggest the intriguing possibility that replace-
ment of IGF-1 to uterine levels might have an impact on the
development of ROP and facilitate normal retinal vascular
development. If phase I is aborted the destructive second phase
of vasoproliferation will not occur.
A rationale for the evolution of ROP: A rationale for the
evolution of ROP has emerged based on the understanding of
the roles of VEGF and IGF-1 in both phases of the disease.
Blood vessel growth is dependant on both IGF-1 and VEGF.
In very preterm infants, with the absence of IGF-1 normally
provided by the placenta and amniotic fluid, blood vessel
growth may be retarded since IGF-1 is required for optimal
VEGF signaling of endothelial cells. When premature infants
are given supplemental oxygen, VEGF itself is suppressed.
Thus both prematurity and oxygen are factors in suppression
of normal vessel growth during phase I of ROP. As parts of
the eye mature without a vascular supply, they become oxy-
gen starved, sending signals to increase VEGF. We postulate
that as the infant’s organ systems mature, IGF-1 levels rise
and suddenly allow the elevated levels of VEGF to promote
neovascular proliferation of blood vessels that can cause blind-
ness.
Clinical implications: The discovery of the possible in-
teractions of VEGF and IGF-1 in the development of ROP
furthers our understanding of the pathogenesis of the disease
(Figure 6). These studies suggest a number of ways to inter-
vene medically in the disease process but also emphasize that
timing is critical to any intervention, since the two phases of
the disease require different approaches. Inhibition of either
VEGF or IGF-1 soon after birth could detrimentally alter nor-
mal blood vessel growth and precipitate the disease whereas
inhibition at the second neovascular phase might prevent de-
structive neovascularization (Figure 6).
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Similarly, replacement of IGF-1 early might promote nor-
mal blood vessel growth while late supplementation with IGF-
1 in the neovascular phase of ROP could exacerbate the
neovascular disease. In the fragile neonate, the choice of any
intervention must be made very carefully to promote normal
physiological development of both blood vessels and other
tissue. In particular, the finding that the low serum levels of
IGF-1 in premature babies may give a new avenue for treat-
ment suggests that correcting the serum IGF-1 levels towards
those found in utero might have a beneficial effect on the dis-
ease by facilitating normal vascular development.
It is also encouraging to find an intervention in the mouse
model of ROP that can prevent vessel loss without precipitat-
ing new vessel growth. Since VEGFR-1 appears to control
vessel survival without instigating proliferation, the use of a
specific agonist to VEGFR-1, PlGF-1, might be used early in
the disease to prevent vessel loss without promoting prolif-
erative disease. Further studies on disease mechanism and
development of strategies to allow normal retinal and brain
development may lead to a significant reduction in the inci-
dence of ROP.
SESSION 2A: CLINICAL STUDIES
Contributors: Dale Phelps, Earl Palmer
This series of presentations brought out many aspects of
ROP that have emerged in the recent years as a result of care-
fully controlled intervention trials, systematic observational
studies of large cohorts, and focused studies of the physiol-
ogy of the retina and its vessels as affected by ROP.
The natural history data and controlled trial results from
Multicenter Trial of Cryotherapy for Retinopathy of Prematu-
rity (the CRYO-ROP Study) provide circumstantial evidence
that peripheral production of growth factors in the avascular
retina is probably the most immediate disturbance leading to
deterioration of the retinopathy. Destruction of that peripheral
retina and the putative source of the growth factors permits
regression (healing) of the ROP in a great many cases. The
visual acuity following ROP has been studied now with grat-
ing and recognition acuity testing through 10 years following
birth. Dr. Dobson describes these findings and shows that the
premature infant develops vision within the normal range over
the early years, even having had mild or moderate ROP. How-
ever, the acuity of the infants who have had threshold ROP
are below the normal developmental range, even when the
eyes have been successfully protected from retinal detach-
ments. The additional finding that the peripheral retina has
poor function (Goldman peripheral fields) at 10 years follow-
ing neonatal threshold ROP, even when the ROP regresses
spontaneously with no cryotherapy (control eyes) was unex-
pected. The detailed studies of the development of photore-
ceptor function described by Dr. Fulton (Session 2D) provides
greater detail and insights into the functional problems en-
countered by photoreceptors in the growing former preterm
infants. Using these functional assessments, children who had
even mild or moderate ROP continue to have measurable defi-
cits in rod sensitivity, although it does appear to be propor-
tional to the severity of the original ROP.
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Figure 6. Schematic representation of IGF-I & VEGF control of blood vessel development in ROP.  A: In utero, vascular endothelial growth
factor (VEGF) is found at the growing front of vessels. insulin-like growth factor 1 (IGF-1) is sufficient to allow vessel growth. B: With
premature birth, IGF-1 is not maintained at in utero levels and vascular growth ceases, despite the presence of VEGF at the growing front of
vessels. Both endothelial cell survival (Akt) and proliferation (mitogen-activated protein kinase) pathways are compromised. With low IGF-
1 and cessation of vessel growth, a demarcation line forms at the vascular front. High oxygen exposure (as occurs in animal models and in
some premature infants) may also suppress VEGF, further contributing to inhibition of vessel growth. C: As the premature infant matures, the
developing but nonvascularized retina becomes hypoxic. VEGF increases in retina and vitreous. With maturation, the IGF-1 level slowly
increases. D: When the IGF-1 level reaches a threshold at 34 weeks gestation, with high VEGF levels in the vitreous, endothelial cell survival
and proliferation driven by VEGF may proceed. Neovascularization ensues at the demarcation line, growing into the vitreous. If VEGF vitreal
levels fall, normal retinal vessel growth can proceed. With normal vascular growth and blood flow, oxygen suppresses VEGF expression, so
it will no longer be overproduced. If hypoxia (and elevated levels of VEGF) persists, further neovascularization and fibrosis leading to retinal
detachment can occur. Republished with permission of the National Academy of Sciences, U.S.A. from Hellstrom A, Perruzzi C, Ju M,
Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE. Low IGF-I
suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci
U S A 2001; 98:5804-8. Copyright 2001 National Academy of Sciences, U.S.A.
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Oxygen and ROP remain linked by the clear demonstra-
tion that, like in the animal models of oxygen induced retin-
opathy, prolonged administration of oxygen so that arterial
levels are elevated will clearly increase the chance of vision
loss from ROP. The discouraging lack of systematic data about
what oxygen saturations (pulse oximetry) are safest for both
the retina and the developing brain are carefully brought out
by Dr. Cole (Session 2F), and there seems to be ample room
for improvement in our knowledge. It is encouraging to learn
that the plans to get such data are finally moving forward on
an international level. In contrast to these planned studies on
the use of oxygen in the early days and weeks after birth, Dr.
Phelps (Session 2E) presented the data from the STOP-ROP
study where enrolled infants already had prethreshold ROP
and were then randomized to treatment with conventional or
increased oxygen as measured by oximetry. While the treat-
ment was theoretically plausible and supported by animal stud-
ies, the effects were small, and not statistically significant ex-
cept in the subgroup identified post hoc who did not have “plus
disease” at the time of randomization. Even in this subgroup,
the effect size was small and not much different than the rates
of adverse pulmonary events from the elevated oxygen levels,
leaving us without the new therapeutic intervention we had
hoped for.
Despite all we have learned, we are left with many ques-
tions, and a few of our favorites are: Why does the pace of
ROP move with postmenstrual age instead of weeks after birth?
Just what is “plus disease”? Why does the peripheral retina
not work after threshold ROP, even when it regressed?
SESSION 2B: LESSONS LEARNED FROM THE CRYO-
ROP STUDY
Contributors: Earl Palmer
We stand in the early years of a new millennium, and it is
fitting to assess what we have learned in the latter half of the
previous millennium. In 1988, the initial report from the
CRYO-ROP Study offered the first proof cryotherapy signifi-
cantly reduces unfavorable fundus outcomes from ROP. In
1990, we reported significant visual acuity benefit from cryo-
therapy, as well. Subsequent publications detailed the small
changes that occurred over time in the group of eyes that re-
ceived cryotherapy, as compared to the control eyes. As with
many well-designed multicenter, randomized clinical trials,
much additional information emerged during the course of the
trial, beyond the primary aim of the study. The CRYO-ROP
study produced abundant new and reliable data concerning
the incidence and early course of ROP, in various subgroups
and according to severity categories.
Brief ROP history: ROP was first recognized in the 1940s.
The role of oxygen was demonstrated in the 1950s, but in the
1960s, the belief that the disease was under control proved
false, and during the 1970s clinicians began to appreciate that
we needed to learn more about this disease. Substantial
progress was made in the clinical recognition of ROP, and by
1984, the international classification of ROP (ICROP) had been
developed and published [96]. During the meetings of that
committee, discussions were held about the advisability of
cryotherapy. The data were inconclusive, but discussions led
to a planning committee to design a clinical trial of cryotherapy.
The Multicenter Trial of Cryotherapy for Retinopathy of
Prematurity: The CRYO-ROP study required detailed devel-
opment of a multi-center infrastructure to determine the risks
and benefits of cryotherapy for ROP, to examine the natural
course of the disorder, and to determine its incidence. Out-
comes of comparably treated and untreated eyes would be stud-
ied; by including a prospective natural history cohort with the
new ICROP, the disease would be better characterized.
Starting in January 1985, infants born were tracked if they
weighed less than 1251 g at birth; 9,751 infants were regis-
tered in 23 participating clinical centers. The cohort of pro-
spectively examined infants who survived for examinations
numbered 4,099. Examinations began at age 4-6 weeks, and
continued every 1-2 weeks, until retinopathy either involuted
or threshold status for randomization into the clinical trial was
attained. Two hundred and ninety-one infants with ROP at
threshold were randomized in the trial. Of these, 79 were “late
entry” and not part of the natural history cohort (infants who
reached the threshold for randomization and were then trans-
ferred into a study center) [97].
To place the CRYO-ROP study into perspective, this was
the first conclusive intervention trial for ROP, and it included
a predetermined sample size to answer the primary question.
The cohort was representative of preterm infants, including
approximately 15% of the premature infants born in the United
States during that time frame [98].
Cryotherapy was chosen (as the method for ablating the
entire area of nonvascularized peripheral retina), because an
indirect-ophthalmoscope delivery system for laser had not yet
been developed that was suitable for use in infants. The opti-
mal dosage and timing of cryotherapy were not studied. The
threshold for randomization was predicted to represent a 50%
risk-severity category, for retinal detachment, and this predic-
tion proved to be surprisingly accurate.
The CRYO-ROP infrastructure included 302 investiga-
tors, located at 77 hospitals in 23 geographic centers around
the United States. This included ophthalmologists, neonatolo-
gists, study center coordinators, ophthalmic photographers, and
the Data Coordinating Center at the University of Texas, Hous-
ton. Many procedures had to be developed. ICROP had to be
refined for research use since plus disease was described in
the ICROP publication only with an example photograph, but
was not specifically presented as a minimum-standard sever-
ity to qualify as plus disease. Therefore, the CRYO-ROP in-
vestigators spent considerable time and effort reviewing fun-
dus photographs, in order to come up with a photograph the
group felt represented the minimum degree of dilatation and
tortuosity to qualify as plus disease. This was published with
the preliminary results of the CRYO-ROP study in 1988 [99],
and has also been used as the standard for three subsequently-
launched multicenter ROP trials sponsored by the NIH (STOP-
ROP, LIGHT-ROP, and ETROP).
The executive committee of the CRYO-ROP study con-
ducted detailed training sessions in the ICROP and in the use
of the data forms. Inter-observer consistency was specifically
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trained by paired examinations, and agreement among cen-
ters was tested by extensive site visiting. The essential ele-
ments of the ICROP were preserved; namely, the definitions
of stages, zones, and the use of the clock-hour convention for
recording the extent of ROP. The ICROP was ambiguous on
the precise definition of zone III, and the CRYO-ROP study
settled on the convention that zones II and III would be mutu-
ally exclusive. Thus, it would be impossible by definition, for
any ROP on the temporal side of the eye to be classified as
zone III, unless the two nasal sectors in the same eye had fully
developed vessels without ROP (a convention also used in the
STOP-ROP, LIGHT-ROP, and ETROP studies).
Objective outcome evaluation was assured by use of naïve
graders of fundus photos, using a system of grading that had
to be developed for this purpose. Visual acuity assessment was
carried out at age one year, under the direction of Dr. Velma
Dobson, using the Teller grating acuity cards. The exact pro-
cedures used to assess visual acuity had to be changed as the
children grew and developed.
Results: By age ten, the majority of treated threshold eyes
have acuity better than 20/200, as compared to only 38% of
untreated eyes. Likewise, the posterior retina was free of fold-
ing or detachment in 73% of treated eyes compared to a bare
majority of control eyes [100]. Color vision, contrast sensitiv-
ity and visual fields were also improved in treated eyes, and
the latter findings were particularly interesting. A physical and
functional price for the benefit of cryotherapy is the reduction
of peripheral visual field by about 5% (compared to sighted
control eyes), but in fact, ROP itself actually reduced the vi-
sual fields nearly as much as did ablation of the
nonvascularized peripheral retina [101].
The current incidence of ROP was determined, and about
two-thirds of all infants weighing less than 1251 g at birth
developed ROP to some degree. Overall, 6% of these infants
developed threshold ROP and were eligible for the random-
ized clinical trial. This was highly correlated with the degree
of prematurity, with 16% of those born weighing less than
750 g reaching threshold for cryotherapy, but only 2% of those
with birth-weights of 1.0-1.25 kg.
A closer look at the timing of events in the natural course
of ROP showed that prethreshold ROP occurred between 32.4
and 41.5 postmenstrual (postconceptional) weeks in 90% of
the infants, for a median of 36.1 weeks. Threshold occurred at
a median age of 36.9 weeks. Involution of ROP started at the
mean postmenstrual age of 38.6 weeks, and 90% of eyes be-
gan to involute between 34 and 46 weeks [102].
Among the outcomes for all eyes in the natural history
cohort (excluding those threshold eyes that were randomized
to be treated), 3.1% had a final outcome of retinal fold or de-
tachment by age 5.5 years. Such unfavorable outcomes were
generally associated with zone II, stage 3 ROP with plus dis-
ease or with zone I ROP. There were only 12 children in the
CRYO-ROP study who had zone I threshold disease fairly sym-
metrically, in both eyes. For them, fundus outcomes were un-
favorable 75% of the time in the eye that received cryotherapy,
as compared with 92% of control eyes. Zone I ROP was un-
common in CRYO-ROP and the investigators learned about
and debated its unusual appearance, particularly the more
subtle signs of stage 3 disease.
An analysis of risk factors showed significant associa-
tions with five ROP variables: stage, extent, zone, plus dis-
ease, and rate of progression of ROP. These were reasonably
predictable, but it was very satisfying to be able to mathemati-
cally describe the magnitude of these effects for the first time
in terms of odds ratios. For risk factors associated with the
infant (as opposed to the eyes), it was already well known that
gestational age and birth weight were significant, but it was
interesting to see evidence that the need for transfer to an-
other hospital following birth was associated with increased
ROP severity. While multiple gestation was not significant in
predicting outcome once an eye reached threshold severity, it
was a predictive factor in the development of ROP per se, and
the likelihood of progressing to threshold severity. A surprise
finding was that African-Americans seem to be relatively re-
sistant to bad outcomes from ROP, despite a similar rate of
early ROP [97]. Hardy combined all of these risk factors to
compute a global risk for a given eye in a given baby. This
risk algorithm, related to adverse fundus outcome at three
months, was used in the ETROP study [103].
Current status of the CRYO-ROP study: More than 50
significant outcome articles have been published since the
primary results appeared in 1988. Final examinations of the
randomized patients were completed at 15 years of age in 2003;
the final manuscript examined the occurrence of retinal de-
tachments between age ten and fifteen years [104].
SESSION 2C: VISUAL FUNCTION IN THE DEVELOP-
ING CHILD FOLLOWING ROP
Contributors: Velma Dobson (on behalf of the CRYO-ROP
Cooperative Group)
The CRYO-ROP study is a multicenter study that con-
sisted of two arms: (1) a natural history study of children with
birth weights <1251 g who had eye examinations in one of the
23 participating centers by 4-6 weeks after birth and (2) a ran-
domized, controlled trial of cryotherapy for eyes that devel-
oped threshold (severe) ROP. The natural history study en-
rolled over 4,000 infants who were born between January 1986,
and November 1987, representing approximately 15% of the
infants with birth weight <1251 g children who were born in
the US during this period. Two-thirds of these infants devel-
oped ROP.
As part of the natural history study, monocular grating
visual acuity was measured with the Teller acuity card proce-
dure [105] in 735 infants at 1 year, 945 children at 2 years,
1,108 children at 3 1/2 years, and 1,173 children at 4 1/2 years
[106]. Results were compared with normative grating acuity
data reported for full-term infants and young children
[107,108]. In the group of children who did not develop ROP
(data obtained from 214 to 380 per test age), mean grating
acuity was near the bottom of the normal range at each age.
Similar results were found for the group of children who de-
veloped only mild (less than prethreshold) ROP (298 to 499
per test age). Mean acuity scores for the group of children
who developed moderate (prethreshold) ROP (65 to 100 per
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test age) were at the bottom of the normal range at each age.
Approximately half of the eyes with threshold ROP that were
randomized to serve as a control (158 to 194 per test age)
were blind, and the remaining eyes showed mean visual acu-
ity well below the normal range at all ages (Figure 7).
Monocular recognition acuity was measured in 959 of
the children at age 5 1/2 years [109] using the Early Treat-
ment Diabetic Retinopathy Study (ETDRS) letter charts [110].
Visual acuity outcome was correlated with severity of acute
phase ROP. Over half of eyes with ROP in zone I or with ROP
in zone II, stage 3 in 7-12 sectors, and plus disease had a vi-
sual acuity of 20/200 or worse. In contrast, over 80% of eyes
with stage 1 or 2 ROP in zone II or with ROP in zone III had a
visual acuity of 20/40 or better at 5 1/2 years.
Two hundred ninety-one infants participated in the ran-
domized trial of cryotherapy for threshold ROP. Of these 291
infants (218 of whom also participated in the natural history
study), 240 had developed threshold ROP in both eyes and
had one eye randomized to undergo cryotherapy and the other
eye served as a control. The remaining 51 infants developed
threshold ROP in only one eye and that eye was randomized
to cryotherapy or to serve as control. Monocular visual acuity
was tested in 68% of the 260 surviving infants at age 1 year
[98], 92% of the 256 survivors at age 3 1/2 years [111], 92%
of the 255 survivors at 5 1/2 years [112], and 97% of 255
survivors at 10 years [100]. As with the children in the natural
history study, testing was conducted with Teller acuity cards
at 1, 3 1/2, and 5 1/2 years, with the crowded HOTV letter test
at 3 1/2 years, and with the ETDRS letter charts at 5 1/2 and
10 years. Unfavorable visual acuity outcome was grating acu-
ity more than one octave below the normal range for age (an
octave is a halving or doubling of grating spatial frequency;
e.g., from 4 to 2 cycles/degree) or letter acuity of 20/200 or
worse. Across all test ages, results indicated an unfavorable
outcome in approximately 60% of control eyes and approxi-
mately 45% of cryotherapy treated eyes, which was a signifi-
cant reduction in unfavorable outcomes in the treated eyes.
Results at 10 years using the letter charts showed that approxi-
mately 25% of both treated and control eyes had acuity of 20/
40 or better [100]. More treated than control eyes had visual
acuity worse than 20/40 but better than 20/200, while more
control than treated eyes had visual acuity of 20/200 or worse,
suggesting that eyes saved from blindness by cryotherapy may
not develop normal visual acuity.
Because cryotherapy ablates the avascular peripheral
retina, Goldmann perimetry was conducted at the 10-year ex-
amination to determine whether study participants showed
visual field deficits [101]. Visual field extent was measured
along eight meridia using the V4e and III4e stimuli and showed
a significant reduction in both treated and control eyes, com-
pared to results from approximately 100 CRYO-ROP study
participants who did not develop ROP. To determine whether
the reduction in mean measured visual field extent in treated
and control eyes was attributable solely to data from blind
eyes (which have a measured visual field extent of zero), we
examined results from 78 patients, each of whom had one
sighted treated eye and one sighted control eye. Measured vi-
sual field extent was still significantly reduced in both treated
and control eyes, in comparison to eyes in the no-ROP group.
In addition, measured visual field extent was slightly (approxi-
mately 5%) smaller in sighted treated eyes than in sighted
control eyes.
In summary, data from the CRYO-ROP study indicate that
the development of visual acuity is related to severity of acute-
phase ROP. Eyes with the most severe acute-phase ROP show
the worst acuity scores at all ages between 1 and 5 1/2 years.
Results from the randomized trial indicate that peripheral reti-
nal ablation using cryotherapy in eyes with severe (threshold)
ROP results in a benefit to visual acuity development, with
only a minimal effect on visual field extent. Nevertheless,
approximately 45% of eyes treated with cryotherapy show sig-
nificant deficits in visual acuity development [98,100,111,112];
visual field deficits are seen in both treated and control eyes
of children who had severe acute-phase ROP [101]. These re-
sults suggest that, despite the benefit of cryotherapy in the
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Figure 7. Acuity development in eyes with quantifiable grating acu-
ity in the CRYO-ROP study.  The shaded area represents the 95%
prediction limits for healthy full-term children with no ocular abnor-
malities reported by Mayer et al. [108]. Not represented in this graph
are eyes with vision too poor to be quantifiable with the Teller acuity
card procedure (less than 3% of eyes in the no-ROP, less than
prethreshold, and prethreshold groups, and approximately 50% of
eyes in the threshold untreated group). Numbers of eyes in each group
at the four test ages, respectively, are: no-ROP (213, 276, 344, 380),
less than prethreshold (295, 384, 468, 496), prethreshold (64, 92, 96,
98), and threshold untreated (78, 89, 94, 98). Bars represent the stan-
dard error of the mean. Republished with permission of The Asso-
ciation for Research in Vision & Ophthalmology from Dobson V,
Quinn GE, Summers CG, Saunders RA, Phelps DL, Tung B, Palmer
EA. Effect of acute-phase retinopathy of prematurity on grating acu-
ity development in the very low birth weight infant. The Cryotherapy
for Retinopathy of Prematurity Cooperative Group. Invest Ophthalmol
Vis Sci 1994; 35:4236-44.
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Figure 8. Visual function and ROP.  A: The growth curve summarizes the developmental increase in human rhodopsin. ROP has its onset just
as the curve begins to increase rapidly. B: The mean and prediction limits for D 10-30 in normal infants; the adult value of zero is reached by
age 6 months. C: Sample ERG records from 10-week-old infants. The vertical scale is in log scotopic troland seconds. The downward
deflections in the records are the a-waves (arrow). The difference between records from the infant with mild ROP and the normal subject are
conspicuous. D: The a-waves are displayed on an expanded time scale. The dashed lines represent the Lamb & Pugh model fitted to the ERG
a-waves. S (rod cell sensitivity) is lower in ROP subjects. E: The mean values of S for “No ROP” and “ROP” subjects are shown as percent of
normal for age. The means differ significantly (re-plotted from Fulton et al, 2001). A: Republished with permission of The Association for
Research in Vision & Ophthalmology from Fulton AB, Dodge J, Hansen RM, Williams TP. The rhodopsin content of human eyes. Invest
Ophthalmol Vis Sci 1999; 40:1878-83. B: Republished with permission of The Association for Research in Vision & Ophthalmology from
Hansen RM, Fulton AB. The course of maturation of rod-mediated visual thresholds in infants. Invest Ophthalmol Vis Sci 1999; 40:1883-6.
C,D: Republished with permission of the American Medical Association from Fulton AB, Hansen RM, Petersen RA, Vanderveen DK. The rod
photoreceptors in retinopathy of prematurity: an electroretinographic study. Arch Ophthalmol 2001; 119:499-505. Copyright ©2001 Ameri-
can Medical Association. All rights reserved.
treatment of severe ROP, there is a need for methods of pre-
venting the development of severe ROP, and a need for im-
proved treatments for eyes that do develop severe ROP.
SESSION 2D: PHOTORECEPTORS AND NEURAL
RETINA IN ROP
Contributors: Anne Fulton, Ronald Hansen
Abnormal blood vessels are the hallmark of ROP. Active
ROP and important developments in the oxygen greedy rods
are concurrent. At preterm ages, the developing rod cells be-
gin redistribution over the growing retinal surface area. The
rod outer segments grow longer causing demands for energy
and oxygen to escalate. The rhodopsin content of the retina
increases (Figure 8A).
We present two types of experiments on the rods of in-
fants and children. We use psychophysical procedures to
sample retinal function in selected, small retinal areas, and
ERG responses to full field stimuli to evaluate function of all
rods in the whole retina. Our subjects are former preterms cat-
egorized according to severity of ROP: none, mild, moderate,
and severe [113].
As background for the psychophysical experiments, we
note that the human eye grows considerably after the preterm
ages when those at risk for ROP are born. By term, the diam-
eter of the eye is about that of a US dime. At post-term ages,
when we measure rod cell function, the globe is still growing.
An adult’s globe is about the size of a US quarter. As the eye
grows, retinal surface area increases. The immature rods re-
distribute over the retinal surface to pave an expanding pe-
ripheral area with a fixed number of rod cells. Redistribution
of rod cells leads to definition of an anatomic ring with a high
number of rod cells per unit area [114,115]. The rod ring is
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concentric with the fovea and at the eccentricity of the disc
(Figure 8B). The developmental elongation of the rods cen-
tral to the ring lags behind that of more peripheral rods [114].
Short outer segments predict lower quantum catch, lower sen-
sitivity, and higher visual threshold.
We devised a preferential looking based psychophysical
procedure suitable for testing, the immature rods central (10°
eccentric) and peripheral (30° eccentric) to the rod ring, in
young infants [116]. We selected test conditions such that in a
dark-adapted adult, the thresholds at 10° and 30° are identi-
cal. By definition, the difference between these thresholds
(“∆10-30”) is zero in adults, but in normal infants, “∆10-30”
is not zero. A longitudinal study following a within subject
design showed “∆10-30” at 10 weeks post-term is on average
0.5 log units, and decreases systematically to the adult zero
by 26 weeks (6 months) as thresholds at both 10° and 30°
reach adult values [117]. Additional evidence [118] demon-
strates rod cell origins of this visual function, in accord with
the anatomic data. The course of development is prolonged in
some ROP subjects, even if ROP is mild [119]. Elevated “∆10-
30” thresholds persist in late childhood in some ROP subjects
[120]. At these older ages, the rod outer segments would have
been turned over and renewed thousands of times. Thus, ROP
injury must not be directed to the outer segment but perhaps
to the inner segment which manufactures the outer segment
discs.
Now we turn to the ERG studies of rod photoreceptor
responses to full field stimuli (Figure 8C). The rod outer seg-
ments are a stack of discs surrounded by the outer segment
membrane. Rhodopsin is in the discs, along with the other
proteins in the transduction cascade. Photon capture activates
rhodopsin, which diffuses in the membrane to activate the G-
protein, which diffuses to activate PDE, which leads to clo-
sure of the cG-gated channels in the membrane.
Each of these biochemical steps can be described pre-
cisely by a mathematical equation, which can be can be sum-
marized in one grand equation, the Lamb and Pugh model
[121-123]. In development, the main parameters of the model
are nicely scaled by rhodopsin content [124,125]. In this equa-
tion the parameter S summarizes kinetics from photon cap-
ture through closure of channels in the outer segment mem-
brane. S represents rod cell sensitivity. S is calculated from
ERG a waves (Figure 8D).
Sensitivity (S) for the No ROP group is indistinguishable
from normal (Figure 8E). Rod cell sensitivity is significantly
lower in those with a history of ROP. Analysis of variance for
data stratified by severity of ROP indicates rod cell sensitivity
varies significantly with severity of ROP [126]. As we con-
tinue to fill experimental cells, we will find out if this holds
for a larger sample.
We conclude that the rods are affected by ROP, even if
ROP was mild. Rod cell dysfunction predicts some visual defi-
cits in ROP. The developmental course of ∆10-30 implicates
the rods in the ROP disease process. Can ERG testing of rod
cell function at preterm ages, before ROP appears, forecast
ROP? We can find out! If rod cell function forecasts ROP,
then timely intervention might prevent ROP.
SESSION 2E: EFFECTS OF OXYGEN ON ESTAB-
LISHED ROP
Contributors: Dale Phelps
The clinician-scientist brings a synthesis of experience,
basic science, theory, epidemiology, and previous clinical re-
search to a clinical trial to determine the safety and efficacy of
a promising intervention. Beyond the strict outcomes of that
trial, secondary analyses reveal new insights and generate new
hypotheses to be tested.
The STOP-ROP study [127] is best understood on the
backdrop of normal human retinal vascular development, de-
scribed elsewhere in these proceedings, and the course of ROP
from its first visible neovascularization 4-11 weeks after birth
[97] through involution or progression to severe disease re-
quiring surgery to reduce the risk of retinal detachment (Fig-
ure 9). The current favored hypothesis of its mechanism is
that following injury to the primitive growing vessels soon
after birth, the retinal vessels begin to re-grow
(neovascularization; NV) and sometimes escape the retina,
growing into the vitreous [96,128]. The retinal vessels most
often grow successfully (80%) and as the retina becomes fully
vascularized, involution of preretinal and intraretinal NV oc-
curs yielding a good outcome. If “plus disease” develops with
its dilation and tortuosity of the vessels in the posterior pole
of the eye (Figure 10), the risk of progression to retinal de-
tachments becomes about 50% [98]. If the avascular retina is
the source of growth factors driving the neovascularization
and plus disease, its ablation would be expected to halt the
progress of the disease. Indeed, surgical ablation (cryotherapy
or laser therapy) of the avascular retina appears to
downregulate the process with disappearance of the plus dis-
ease and return of the eye to a quiet state, but there is no fur-
ther vascularization of the now scarred and non-functional
peripheral retina [98]. In the STOP-ROP hypothesis, we ex-
tended the concept: if hypoxia of the neuroretina was causing
the growth factor release, perhaps raising the diffusion gradi-
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Figure 9. Rationale for the STOP-ROP study.  Artist’s concept of the
sequential appearance of the growing preterm human retina as it de-
velops ROP. From left to right, the normal immature retina, initial
injury of the developing vessels, neovascularization with plus dis-
ease, involution (top) or retinal detachment (lower). The red arrow
and circle indicates the hypothesized time/site of action of oxygen in
the STOP-ROP study.
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Figure 10. Fundus photography of plus disease in ROP.  Photographs of the posterior pole of human infants demonstrating the normal vascular
pattern (left), and venous dilation and arteriolar tortuosity of “plus disease” (right). RetCam photos courtesy of Massie Labs (now Clarity
Medical Systems, Inc.), Pleasanton, CA.
ent of oxygen from the choroid could allow downregulation
of the growth factor production (without turning it completely
off) and permit orderly new vascularization.
In the STOP-ROP study [127], infants who developed
prethreshold ROP [99] were enrolled from 30 centers and ran-
domized to maintain pulse oximetry of 89-94% oxygen satu-
ration (conventional treatment [C]; n=325) compared to 96-
99% saturation (supplemental treatment [S]; n=324; Figure
11). The randomization balanced the groups well and the treat-
ment was administered consistently. We found that 48% of
the C group went on to meet surgery criteria compared to 41%
of the S group (p=0.06). The total magnitude of the difference
(which was not statistically significant, but in the expected
direction) was not large and, at 3-6 months past their due dates,
these preterm infants had essentially the same rates of poor
eye outcomes (retinal detachment, retinal fold, obstruction of
the visual axis) in both groups (4.4% for the C group and 4.1%
for the S group). There were increased pulmonary side effects
in the S group, so with its small potential benefit, this treat-
ment is not widely used now. However, in a secondary analy-
sis, some tantalizing biology emerged.
For the STOP-ROP trial, the prethreshold ROP entry cri-
teria was: stage 3 ROP in zone II; plus disease in zone II with
stage 2; zone II without enough stage 3 to meet threshold-for-
surgery criteria; or any ROP in zone I, even with no plus dis-
ease [99]. Examination of the enrolled infants showed that 2/
3 of the enrollees did not have plus disease as a component of
the reason for their having prethreshold ROP. This was equally
balanced in the C and S groups. The birth weights and gesta-
tional ages of these two subgroups were similar and, there-
fore, the outcomes were examined according to whether they
had plus disease or not at study entry. If plus disease was
present at the time of randomization, 55% of the infants went
on to meet the surgery criteria, clearly a marker of severe dis-
ease; however, supplemental oxygen had no differential ef-
fect on eyes that already had plus disease (57% going on to
threshold in the S group compared to 52% in the C group). In
contrast, the outcomes were significantly different among the
eyes that did not have plus disease at the time of randomiza-
tion. Eyes of infants in the C group progressed to threshold
46% of the time while those in the S group progressed only
Figure 11. Predicted arterial PaO2.  Relative arterial oxygen levels in
human infants with normal lungs breathing 50% oxygen (animal
models of ROP breathing 80-100% oxygen are even higher), and the
levels among premature infants receiving oxygen where attempts are
made to minimize the amount of oxygen given. Infant’s in the supple-
mental group in STOP-ROP had somewhat higher levels, as labeled.
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32% of the time (p=0.004) [127]. This suggests that systemic
oxygenation status does effect rates of progression in human
ROP if administered before plus disease occurs. This has been
replicated in the mouse and kitten models, where the
neovascularization and VEGF expression were both reduced
when oxygenation status was increased [36,39,90]. It also sug-
gests that when plus disease develops, there is a major change
in the pathophysiologic process that is occurring, and it is likely
to lie in the complex mix of proangiogenic and antiangiogenic
mechanisms ongoing in the retina. We do not yet understand
what happens in ROP to result in plus disease, but progres-
sion to early retinal detachments rarely ever occurs without
the retina developing plus disease first.
The STOP-ROP trial disappointed clinicians and bench
scientists who sought a gentle intervention (supplemental oxy-
gen) allowing infants with ROP to complete spontaneous in-
volution and healing of prethreshold ROP. However, it also
suggested that the key finding of “plus disease” is a greater
turning point in the control of ROP than was previously sus-
pected, and that it should be further investigated in order to
understand this developmental retinopathy.
SESSION 2F: CAN EARLY OXYGEN RESTRICTION
PREVENT ROP AND IS IT SAFE?
Contributors: Cynthia Cole
Oxygen is the one of the most common neonatal thera-
pies [129]. Unfortunately, very premature infants are particu-
larly sensitive to its toxic effects [130-133]. The optimum range
of oxygen saturation in the first few weeks is unknown and no
randomized trial has addressed this question [134,135]. Thus,
oxygenation management of Extremely Low Gestational Age
Neonates (ELGANs; under 28 weeks gestation) is a major di-
lemma and challenge.
The intense interest in oxygenation of ELGANs is driven
by concerns that current practices in many nurseries target
oxygen saturation (SpO2) ranges above 90% and that higher
SpO2 ranges appear to contribute to oxygen-related morbidi-
ties, such as severe ROP and chronic lung disease (CLD). ROP
and CLD are both associated with subsequent
neurodevelopmental impairment. CLD is also associated with
poor growth and long-term respiratory morbidity. These con-
cerns are further intensified by findings from recent cohort
studies which suggest that lower SpO2 policies (less than 90%
saturation) and strict oxygenation management are associated
with less ophthalmic and pulmonary morbidity without ad-
verse effect on mortality, neurodevelopment, and growth [136-
139].
Proponents who favor higher SpO2 targeted ranges (over
90%) are concerned that the lower saturation approach of oxy-
gen therapy may be “insufficient oxygen” and that this would
lead to poor growth, neurodevelopmental impairment, and pos-
sibly increased mortality. Additional concerns are that restric-
tive oxygen therapy would increase patent ductus arteriosus,
raise pulmonary vascular resistance, and increase apnea and
bradycardia. Numerous newborn animal studies clearly dem-
onstrate evidence of OIR [55,140-144]. Ashton et al. [28,141]
showed that exposure of newborn kittens to lower oxygen
concentrations (10-15%) for 10 days resulted in mild
neovascularization. Phelps et al. [145] showed that continu-
ous exposure to lower oxygen (13% or 17% from birth through
3 weeks) facilitated or even accelerated growth of retinal ves-
sels in kittens. In contrast, breathing 21%, 30%, and 40% oxy-
gen increasingly impaired retinal vessel development up to
complete vessel ablation when reared breathing 80% oxygen.
McColm et al. [146] reported the effect of oxygen fluctua-
tions around different mean oxygen levels (17%, 21%, 24%)
on retinal vessel development in rat pups. Rats raised in a 17%
variable oxygen environment developed less severe vascular
abnormalities than those raised in variable oxygen environ-
ment around a higher mean of 21% and 24%. Research by
McColm et al. [146] provides additional evidence that expo-
sure of immature retinas to lower oxygen, even with oxygen
lability, reduces abnormal vessel development and that small
increases in oxygen with oxygen lability contributes to abnor-
mal retinal development. Analyses of oxygen fluctuations
around different mean oxygen concentrations (17%, 21%,
24%) on the rat pups’ lungs and central nervous system is pend-
ing (personal communication, J. McColm and N. McIntosh).
Human studies: The first multicenter, randomized clini-
cal trial involving neonates demonstrated that restricted pro-
longed oxygen therapy reduced the risk of cicatricial retrolen-
tal fibroplasia (RLF, as ROP was initially known) by two thirds
compared to unrestricted prolonged oxygen therapy [147-149].
Two separate meta-analyses of the early RLF trials [37,78,149-
152] reaffirmed that restricted oxygen was associated with re-
duction, though not complete elimination, of both overall RLF
and severe RLF. Inappropriate extrapolation of results from
the RLF trials of the 1950s led to the belief that RLF could be
reduced if oxygen concentrations did not exceed 40% [147].
Widespread restriction of oxygen therapy to no more than 40%
for premature infants was associated with a dramatic reduc-
tion in blindness due to RLF. Unfortunately, the uncritical ac-
ceptance and untested restriction of oxygen therapy in the
manner practiced after the RLF trials also resulted in increased
mortality and cerebral palsy [153,154]. For every infant whose
sight was saved, it is estimated that 16 died and many others
developed spastic diplegia [155,156].
Four recent cohort studies suggest that lower rather than
higher oxygen saturation alarm limits or policies in very pre-
mature infants may reduce severe ROP and chronic lung dis-
ease and improve growth without increasing adverse outcome
[136-139]. Tin et al. reported that lower SpO2 alarm limits
correlated with improved outcomes in infants born less than
28 weeks gestation [136]. Alarm limits for SpO2 in four inten-
sive care units ranged from 70-90% to 88-98%. Babies in the
unit with SpO2 alarm limits of 70-90% had less ROP surgery
than babies in the NICU with SpO2 alarm limits of 88-98%
(6.2% compared to 27.2%; 80% relative risk reduction [RRR];
p<0.01). Survivors from the NICU with SpO2 alarm limits of
70-90% (compared to survivors from the NICU with SpO2
alarm limits of 88-98%) were ventilated fewer days (13.9 com-
pared to 31.4 days), fewer needed oxygen at 36 weeks
postmenstrual age (18% compared to 46%; 61% RRR), and
fewer were below the third centile for weight at discharge (17%
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compared to 45%; 62% RRR; p<0.01 in all). Survival (52%
compared to 53%) and cerebral palsy (15% compared to 17%)
at one year were similar. In a preliminary analysis of 2 and 10
year outcomes of this same cohort who received care in nurs-
eries with “low” (70-90%) or “high” (88-98%) targeted SpO2
alarm limits, Tin et al. [157] recently presented that there was
no difference in survival with or without disability.
Anderson [137] reported that units with functional SpO2
upper limits of 92% and less compared to over 92% had less
Grade III/IV ROP (2.4% compared to 5.5%; p<0.001) and less
ROP surgery (1.3% compared to 3.3%; 61% RRR; p<0.037).
Sun [138] studied 1544 infants weighing under 1 kg in units
with upper limit SpO2 of 95% or less compared to over 95%.
Units with the lower targets had less stage 3 ROP (10% com-
pared to 29%; p<0.001), surgery (4% compared to 12%; 67%
RRR; p<0.001), chronic lung disease (27% compared to 53%;
49% RRR; p<0.001) and similar mortality (17% compared to
24%).
Chow et al. [139] reported the four year experience of a
new strict oxygenation management policy which emphasized
avoidance of extreme swings in oxygen saturation, new SpO2
target ranges of 83-85% to 93% for infants up to 32 weeks
and sick infants. Compared to historic controls before (1997)
and after (1999-2001) implementation of the new protocol,
ROP stage 3-4 decreased from 12.5% to 2.5% (p=0.01) and
threshold from 4.4% to 1.3% in infants with birth weight un-
der 1500 g. Although numbers for other outcomes were small,
there was no increase in bronchopulmonary dysplasia, intrac-
ranial hemorrhage, cerebral palsy, hearing loss, or mortality.
Survival tended to improve after the protocol change (81% to
90% for infants under 1.5 kg; 48% to 75% for infants between
0.5 and 0.75 kg).
Schulze et al. [158] reported in ventilated preterm infants
(n=20; 25-33 weeks gestation, age 11-96 h) that a fractional
SpO2 range of 89-92% compared to 93-96% permitted less
oxygen exposure without causing compensatory increase in
cardiac output or compromising tissue oxygen delivery or
oxygen consumption. They concluded that “lower” SpO2 al-
lowed for less oxygen exposure without deleterious cardio-
vascular effects or compromise in systemic oxygen delivery.
Skinner et al. [159] studied hemodynamic effects of the
SpO2 ranges 84-88%, 95-97%, and 96-100% (10-15 min) in
18 infants with respiratory failure (mean gestational age 31
weeks, range 28-36 weeks; age 9 to 76 h). Increasing the satu-
ration from 84-88% to 95-97%, did not significantly change
pulmonary artery pressure. Studies during acute hyaline mem-
brane disease failed to show a convincing link between pul-
monary arterial pressure and arterial oxygenation [160,161].
This is in contrast to studies of babies with established bron-
chopulmonary dysplasia (BPD) that demonstrated increasing
SpO2 is a potent pulmonary vasodilator [162,163].
Bard et al. [164] found that a decrease in SpO2 from 95%
to 90% in preterm infants at a mean age of about 62 h did not
effect pulmonary circulatory hemodynamics, or ductus arte-
riosus.
Conclusion: Despite accumulating evidence that restricted
oxygen management may be beneficial in reducing oxygen-
related morbidities such as severe ROP and chronic lung dis-
ease, the safety and efficacy of this goal has not been demon-
strated in a clinical trial. Even if a lower SpO2 range decreases
rates of ROP, it is not known if this potential benefit may be
offset by possible increased rates of adverse outcomes such as
mortality and neurodevelopmental delay or later learning dis-
orders. Lack of definitive evidence as to what SpO2 range
maximizes benefit and minimizes harm in premature infants
provides the ethical and scientific imperative to study untested,
current practices. A pragmatic, randomized, masked, clinical
trial is needed to define an optimum target SpO2 range.
SESSION 3A: ROP - A LIFETIME DISEASE
Contributors: Michael Repka, John Flynn
Numerous problems associated with ROP continue to con-
front physicians. In the developed and developing world alike
there is great difficulty ensuring adequate availability of eye
examinations for ROP and facilities with experienced treating
physicians. Results of the Early Treatment Study which found
a benefit of early treatment will only serve to increase those
demands as these results are translated into clinical practice
necessitating more frequent examinations. Screening for ROP
may be eased in the future by the implementation of new im-
aging technologies. Advanced ROP (stages 4 and 5) remains
difficult to treat successfully, but good visual outcomes have
been found in uncontrolled series after lens-sparing vitrectomy
for stage 4A. Beyond childhood, serious ROP confronts pa-
tients with retinal detachment, early cataract formation, and
myopia, aspects of the disease which need to be taught to all
ophthalmologists.
SESSION 3B: MANAGEMENT OF ATYPICAL STAGE 3
AND STAGE 4 ROP
Contributors: Michael Trese
As smaller and smaller babies are kept alive, an increased
incidence of posterior ROP has been observed. With this pos-
terior disease, the appearance of neovascularization changes
from the typical neovascularization extending into the vitre-
ous cavity, anterior to the retinal ridge, to more flat
neovascularization without ridge tissue. This appearance now
has become more familiar to the ophthalmologist, and with
that the treatment pattern has changed.
Treatment of atypical posterior stage 3 ROP: All would
agree that treatment should be to the avascular retina and should
include the avascular retina that is beneath the frond of flat
neovascularization that lies along the retinal surface. The treat-
ment is also extended anterior to the area of, but not includ-
ing, the shunt vessels. These vessels have been referred to as
“naked” shunt vessels as they are not enclosed in ridge tissue.
By including this area of avascular retina, the chance of pro-
gression to retinal detachment is reduced. The treatment pat-
tern however does produce small amounts of punctate hemor-
rhage in the area of the flat neovascularization. This aggres-
sive posterior disease, however, can still lead to retinal de-
tachment, even with appropriate treatment pattern and treat-
ment timing. Recent evidence for the need for this timing has
been contributed by the Early Treatment Retinopathy of Pre-
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maturity Study. When such detachments occur, we aim to de-
tect them early for further intervention.
Treatment of stage 4 retinal detachment: We seek to de-
tect these retinal detachments at the 4A stage. With the advent
of lens-sparing vitrectomy for stage 4A ROP, we have found
that we are often able to halt the progression to stage 5 ROP
and to achieve retinal reattachment in a high percentage of
eyes ranging from 86 to 90+% [165-167]. In addition, we have
found that by operating on eyes before the center of the macula
detaches, our visual results can also improve, with measured
acuity ranging from 20/20 to 20/200, as reported by Prenner
et al. [168]. The circumstance of timing of lens-sparing
vitrectomy is based on the natural history observations of the
CRYO-ROP study, which showed that in eyes with a
postmenstrual (PMA) age consistent with active disease (up
to 50 weeks PMA) that progression to stage 5 in eyes with 12
ROP sectors (the 3 ROP zones with a clock superimposed) of
retinal detachment were as high as 92%. In addition, unfavor-
able outcomes were present in eyes that had as little as 1 to 3
sectors of retinal detachment at an active period. Therefore
early intervention with vitrectomy for stage 4A certainly seems
appropriate.
The risks of vitrectomy include infection, endophthalmitis,
and damage to the lens or retina, which could render the child
blind. If retinal tears are present and unable to be repaired,
blindness is also likely. The risk, however, is much less than
the risk of the eyes progressing to stage 5 disease. I think in
most centers now vitrectomy for stage 4A is an accepted pro-
cedure.
SESSION 3C: ROP: LATE COMPLICATIONS IN THE
BABY BOOMER GENERATION (1946-1964)
Contributors: Bradley Smith, William Tasman
Prior to the 1940s, ROP was an unknown disease, in part
because severe prematurity was usually fatal. The period be-
tween the 1940s and the introduction of ROP treatment in the
1980s resulted in a cohort of baby boomers with ROP that
escaped initial treatment. While the disease continues to af-
fect infants of especially low birth weight and gestational age
[169] effective treatment is now available with cryotherapy
or laser [100,170,171]. Complications of more severe stages
of ROP include myopia, early development of cataracts, iris
neovascularization, glaucoma, retinal pigmentation, retinal
folds, dragging of the retina, lattice-like degeneration, retinal
tears, and, rhegmatogenous and exudative retinal detachments
[172-177]. This report presents a review of older children and
adults with ROP born during a time when neither a generally
accepted form of treatment nor the definitive international clas-
sification of ROP (ICROP) was available [96,99].
Participants and methods: The study population included
all referral patients aged 45 years or older from the authors’
practice who were diagnosed with ROP as infants. After ap-
proval by the Institutional Review Board, charts were reviewed
for birth weight, gestational age, present age, gender, poste-
rior segment pathology, prior surgery, refractive error, phakic
status, glaucoma and best-corrected visual acuity as measured
with the Snellen charts.
Findings: Forty-seven patients were identified with 86
eyes (8 were enucleated). The mean current age was 49.9 years
with a range of 45 to 56 years. Birth weights (known in 36
patients) ranged from 680 to 2438 g with a mean of 1251 g;
the mean gestational age (known in 32 patients) was 28.2 weeks
with a range of 20 to 36 weeks recorded. Thirty-three patients
(70.2%) were female and 14 were male (29.8%) suggesting
that females may have had a greater tendency to survive than
did males as previously reported [178]. In a recent database
review of Jefferson Hospital’s neonatal intensive care nurs-
ery, however, babies 1250 g or less born between June 1995
and August 2003 had a 24.1% prevalence of stage 3 ROP for
each gender.
Posterior segment: Seventy-six of the 86 eyes (88.4%)
had posterior segment pathology due to ROP. The remaining
10 eyes demonstrated other forms of regressed ROP. Retinal
dragging was the most common posterior segment pathology
occurring in 29 of the 86 eyes (33.7%).
Retinal detachments: Retinal detachments occurred in 22
eyes (25.6%): five exudative and 17 rhegmatogenous. The
exact date of retinal detachment onset was known for 11 eyes.
The average age of onset for all retinal detachments was 35
years of age with a range of 14 to 51 years. Three eyes with
exudative detachments were successfully reattached using
cryotherapy, scleral buckling, and vitrectomy with buckling.
Two eyes treated with scleral buckling alone failed to reat-
tach. Twelve eyes with rhegmatogenous retinal detachments
were successfully buckled and two were reattached after
vitrectomy with scleral buckling. Vitrectomy was unsuccess-
ful in one eye as was scleral buckling in two others. In all, 17
of the 22 eyes with retinal detachments (77.3%) were reat-
tached. Two of the failures were exudative detachments and
three were rhegmatogenous.
Nine eyes (10.5%) had retinal pigmentation and 8 (9.3%)
had lattice-like degeneration. Retinal tears occurred in seven
eyes (8.1%) and were treated with cryotherapy (five eyes) and
laser (two eyes). Six eyes (7.0%) had retinal folds and five
eyes (5.8%) had posterior vitreous detachments. The preva-
lence of macular holes, epiretinal membranes, chorioretinal
scars, and retinal pigment epithelium changes was 2.3% each.
Lacquer cracks occurred in one eye, as did a macular star
(1.2%).
Acuity and refractive errors: The best-corrected visual
acuity (BCVA) was 20/30 or better in 23 of the 84 eyes that
could be tested (27.4%; Table 1). Eighteen eyes (21.4%) had
a BCVA between 20/30 and 20/200 while 43 eyes (51.2%)
were 20/200 or worse.
The refractive error was known for 43 of the 86 eyes (Table
2). Thirty-nine of 43 eyes (90.7%) showed some degree of
myopia ranging from -0.50 to -22.00 D with a mean of -5.71
D. Fourteen eyes (32.6%) were highly myopic (≤-6.00 D), 19
(44.2%) were moderately myopic (>-6.00 D but ≤-2.00), and
six (14.0%) were mildly myopic (>-2.00 but <zero). Four eyes
(9.3%) were either emmetropic or hyperopic. Only ten refrac-
tions were known for the 20 eyes that received a scleral buckle.
The range for this subgroup was from -0.50 to -6.25 D with a
mean of -3.63 D.
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Lens status: Fourteen of the 86 eyes (16.3%) had a clear
natural lens while the remaining 72 eyes (83.7%) had a cata-
ract, implant, or were aphakic. Stated another way, 35 patients
(74.5%) had cataract surgery on one or both eyes while only
12 (25.5%) retained their natural lenses. Nuclear sclerosis was
the most common type of cataract occurring in 13 of the 29
phakic eyes (44.8%) who had not undergone cataract extrac-
tion.
Cornea and glaucoma: Band keratopathy developed in
five eyes (5.8%) and two eyes (2.3%) had opaque corneas.
The remaining 79 eyes (91.9%) had clear corneas. Fourteen
of the 86 eyes (16.3%) had some form of glaucoma. Six (7.0%)
had narrow angles treated with laser peripheral iridotomy.
Open-angle glaucoma occurred in five eyes (5.8%). Three eyes
(3.5%) were diagnosed with neovascular glaucoma. One was
treated with panretinal photocoagulation (PRP), one with a
shunt tube, and one with a shunt tube in addition to PRP.
Discussion: Eight eyes (9.3%) of the patients in this study
were enucleated (indications for enucleation were not known),
but these eyes probably represent the terminal consequences
of ROP. The remaining 86 eyes available for review all had
regressed ROP, and 88.4% had some residual posterior seg-
ment pathology. As in previous studies, these findings high-
light the need for lifelong follow up of patients who have been
diagnosed with ROP [176].
Interestingly, the average age at onset for retinal detach-
ment in this group was 35 years. Twenty of the 22 eyes with a
retinal detachment were treated with a scleral buckling proce-
dure for a success rate of 80%, similar to other published se-
ries treating late retinal detachments in ROP [176-178]. Two
of the unsuccessful cases were exudative retinal detachments.
Previous studies have also demonstrated a correlation be-
tween the severity of early acute ROP and the development of
myopia [113,173,179,180]. The acute early stage of ROP for
each patient in this present study is not known, but was likely
to have been severe in order for them to be referred to the
retinal practice. Despite regression of disease, 90.7% of the
eyes (where refractive information was available) were found
to be myopic at the time of review. Twenty-four of 37 eyes
(64.9%) were found to have persistence of or progression of
myopia at six months of age. Our study also demonstrates a
high incidence of myopia in adults with ROP. The refraction
was known for half the eyes with a buckle. Eyes with a scleral
buckle had a mean of -3.63 D for this group of myopia com-
pared to -5.71 D for the entire study cohort suggests the rate
and degree of myopia for most was due to causes other than
scleral buckling alone, although a buckle may induce higher
myopia.
Glaucoma is another recognized threat to vision in in-
fants with ROP, even with the retina attached [172]. Smith et
al. [181] reported three cases of acute-angle closure glaucoma
occurring in patients with ROP, and all were treated success-
fully using miotics and either surgical or laser iridotomy. These
outcomes suggest pupillary block as the mechanism. Six of
our patients had narrow angles warranting peripheral
iridotomies. In this review there was no correlation with pos-
terior segment disease such as retrolental membranes in eight
of the 14 cases of glaucoma. Three eyes developed neovascular
glaucoma. This was presumed to occur due to stimulation of
angiogenic factors from avascular retina leading to
neovascularization of the anterior segment. Two eyes were
treated with panretinal photocoagulation in an effort to halt
the process of neovascularization.
BCVA is the most important measure of outcome. Unfor-
tunately, 51.2% of the eyes in this retrospective review had a
BCVA of 20/200 or less. However, good BCVA is still pos-
sible despite ROP as demonstrated by Ferrone et al. [182] in
his series of patients with marked posterior segment changes
secondary to ROP; we had similar results. For example, 13 of
27 eyes (48.1%) with retinal dragging and known BCVA had
a visual acuity of 20/60 or better (Table 3). Eyes with only
retinal pigmentary change and no other ROP findings were
the most likely to achieve good visual function. In contrast
only one of six eyes (16.7%) with retinal folds had a BCVA of
TABLE 1. BEST-CORRECTED VISUAL ACUITY
                         Number out
                         of 84 known
        BCVA           visual acuities
--------------------   ---------------
            >=20/30      23 (27.4%)
<20/30  and >=20/60      12 (14.3%)
<20/60  and >=20/100      6  (7.1%)
<20/100 and >=20/400     12 (14.3%)
Count fingers            11 (13.1%)
Hand motion               9 (10.7%)
Light perception          4  (4.8%)
No light perception       7  (8.3%)
Best-corrected visual acuity in 84 of 86 ROP eyes.
TABLE 2. REFRACTIVE ERROR IN ROP
                       Number out
Spherical equivalent   of 43 known
of refractive error    refractions
--------------------   -----------
            <=-6.00    14 (32.6%)
 >-6.00 and <=-2.00    19 (44.2%)
 >-2.00 and <= 0        6 (14.0%)
 >0                     4  (9.3%)
Refractive error in 43 ROP eyes.
TABLE 3. POSTERIOR SEGMENT PATHOLOGY BY VISUAL ACUITY
                        Dragging      Retinal    Retinal    Retinal    Retinal
                       (27 of 29    detachment     tear     pigment      fold
        BCVA           VAs known)    (22 eyes)   (7 eyes)   (9 eyes)   (6 eyes)
--------------------   ----------   ----------   --------   --------   --------
            >=20/30        9         5              2          3          0
<20/30  and >=20/60        4         5              1          2          1
<20/60  and >=20/100       4         0              0          1          0
<20/100 and >=20/400       3         4 (3 ERD)      2          1          0
Count fingers              2         2 (1 ERD)      2          0          2
Hand motion                3         2              0          1          1
Light perception           2         3 (1 ERD)      0          0          1
No light perception        0         1              0          1          1
The relationships observed between best-corrected visual acuity
(BCVA) and ocular pathologies like retinal traction or dragging.
Counts for exudative retinal detachments (ERD) are also given.
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20/60 or better; this group of eyes had the poorest visual prog-
nosis.
Summary: ROP can be a devastating eye disease in pre-
mature infants. Developments in treatment such as cryotherapy
and laser photocoagulation have reduced vision-threatening
complications, but life-long follow up of these patients is re-
quired.
SESSION 3D: ROP IN THIRD WORLD AND MIDDLE
DEVELOPED COUNTRIES
Contributors: Sjakon Tahija
Indonesia’s population was 206 million, growing at a rate
of 1.49% annually, and the gross income per capita in 2002
was US$710 according to the BPS-Statistics Indonesia. In-
fant mortality in 2002 was reported by the WHO in 1997 to be
between 26 to 39.4 deaths/1000 live births. These statistics
would probably categorize Indonesia as being a middle de-
veloped country.
Problems in health care in Indonesia are similar to other
under or middle developed countries, with limited government
resources allocated to areas with the greatest needs. Most likely
the problems in management of ROP in Indonesia would also
reflect similar situations in other third world and middle de-
veloped countries.
The main causes of blindness according to a 1997-1998
Indonesian Department of Health survey of eight provinces
are presented in Table 4. When the incidence of population
effected by a disease is less than 0.5%, there is usually no
special government program. This is why there is a cataract
eradication program in Indonesia but none for the other eye
diseases.
According to the World Health Organization between
1995-1999, 8% of infants in Indonesia had low birth weights,
however there are no data on premature births nationally.
In Indonesia it appears that there are two causes of ROP
in neonatal intensive care wards. The first cause of ROP is the
relatively recent success in saving low birth weight (LBW)
and very low birth weight (VLBW) infants, which has not
been matched by an increased awareness to screen for and
treat ROP. This is a new problem because previously these
infants did not survive. Despite economic problems in Indo-
nesia, there have been very significant advances in private
health care, fueled by the demand created by a growing middle
class. In most areas of Indonesia, babies with a birth weight of
1500 g or lower do not survive, however, in a few private
hospitals it is common for babies with a birth weight of 1000
g to survive, and at times babies with a birth weight of 800 g
are being saved. This success in saving LBW and VLBW in-
fants was not followed by awareness in preventing ROP. Con-
sultation to ophthalmologists was usually only done after the
baby had stage V ROP. To prevent vision loss from ROP it
was necessary to improve awareness of (1) neonatologists
usually through personal communication, (2) ophthalmologists
by giving courses and training in examining neonates, and (3)
the general public by using television and other mass media
tools. A high profile legal case against a hospital and neona-
tologist by the parents of a stage V ROP infant who was not
screened in time to be offered peripheral retinal ablation has
ironically provided the help needed to draw attention to the
need for timely screening in ROP.
The second cause of ROP is the use of high and
unmonitored concentrations of oxygen in neonates which are
at risk due to septicemia or other reasons. These infants would
not normally be classified as high risk for ROP; however, the
high concentrations of oxygen used in treatment can cause
ROP in neonates who would normally be at low risk. These
neonates are usually in government facilities where the main
attention is to save their lives. In one case, a child with a birth
weight of 2500 g developed ROP. The solution to this prob-
lem would appear to be making available instruments to mea-
sure oxygen concentration in these neonates.
Our goals are (1) to increase awareness regarding risk
factors leading to ROP, (2) to have all neonates at risk of ROP
examined by an ophthalmologist, (3) for babies needing treat-
ment to be referred on a timely basis to a hospital with either
indirect laser or cryotherapy facilities available, and (4) to pro-
vide oxygen monitoring devices to neonatal intensive care
wards.
Although in a developing country like Indonesia, ROP is
not a serious problem from a public health perspective, it is a
great tragedy both for the children affected and their families.
It is even more tragic that many of these cases of blindness
due to ROP are caused by ignorance of the healthcare provid-
ers. Hopefully with better education and some funding for
equipment, such as indirect ophthalmoscopes and oxygen
monitoring devices, these cases of unnecessary blindness can
be avoided in the future.
SESSION 3E: SCREENING FOR ROP IN THE UNITED
STATES?
Contributors: John Flynn
The title of this paper is punctuated with a question mark.
Why? It is because I believe this word, “screening,” to be a
misnomer. The characteristics of a screening procedure [183]
and a successful screening program are listed in Table 5 and
Table 6.
We ophthalmologists are responsible for performing a di-
agnostic examination of the premature infant’s at-risk eyes.
On the basis of that examination, we must make a diagnosis
of the presence or absence of ROP, and form a prognosis should
ROP be present. Finally, and most importantly, on the basis of
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TABLE 4. BLINDNESS IN INDONESIA
 Blindness etiology    Prevalence   Persons affected
--------------------   ----------   ----------------
Cataract                 0.78%         1,600,000
Glaucoma                 0.3%            600,000
Retina                   0.1%            200,000
Cornea                   0.1%            200,000
Refractive disorders     0.1%            200,000
The main causes of blindness reported by an Indonesian Department
of Health survey of eight provinces in 1997-8. Percentages listed are
based on the survey result with the number affected extrapolated to
the total population.
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Figure 12. System for
screening, diagnosis, and
treatment of ROP in the
future.  Model for ROP
management in the future
that includes support, op-
erations, and follow up.
This proposed system will
vastly improve the effi-
ciency of care for the ROP
patient and the caregivers.
TABLE 5. CHARACTERISTICS OF A SCREENING PROCEDURE
Application of test or procedure to asymp-
tomatic subjects
Classifiy them by risk of disease
Screening does not diagnose disease
Performed by nonprofessional
Important characteristics of a procedure to be used in a screening
program as described by Hennekens et al. [183].
TABLE 6. CHARACTERISTICS OF A SUCCESSFUL SCREENING PROGRAM
Disease is appropriate for screening
Disease has a high prevalence in target
population
Serious consequences if undetected
Screening is sensitive/specific
Effective treatment is available
Cost effective/ethical
Essential characteristics in applying a screening procedure to a full
screening program that is cost effective and prevents morbidity as
described by Hennekens et al. [183].
556
©2006 Molecular VisionMolecular Vision 2006; 12:532-80 <http://www.molvis.org/molvis/v12/a63/>
Figure 13. Digital fundus photographs of ROP.  A: Original digital
fundus photograph of ROP. B: The original image was enhanced by
increasing contrast, subtracting the red and a little blue for better
appreciation of the ridge and retinal blood vessels.
that examination, we must determine a treatment plan. If ROP
is not present then it becomes our obligation to determine when
follow up examinations should occur to exclude with reason-
able probability ROP as a threat to the premature infant’s vi-
sion. Is that screening? Most assuredly it is not. If one finds
this hard to accept, ask any experienced medical malpractice
trial lawyer. Is this a trivial misnomer? Not in the least, for it
denigrates the skills we bring to the child’s examination. Most
likely should it continue to be called “screening” unchecked
we will find our colleagues in the third party payor world ea-
ger to take us at our valuation of ourselves and reward us ac-
cordingly. I have a better name for what we do: Retinopathy
of Prematurity Examination and Diagnosis or “ROPED” for
those who find acronyms congenial.
Next let us look for the current guidelines for “Screen-
ing” (verbum horribilis) in the United States [102,184]. These
two works, although proffered only as guidelines, may take
on an almost biblical significance, especially in the hands of
tort lawyers, in malpractice actions against physicians who
may have experienced an unfavorable result in treating an in-
fant with ROP. Most assuredly they are not dogma. They
merely represent a mixture of evidence drawn from a large
pool of examinations and the intuition/wisdom of clinicians
experienced with the disease. All the more reason to word such
documents extremely carefully, stressing their limits, and what
they do not represent, as much as what they do. Parsimony of
verbiage and accuracy in the use of language should be their
hallmark. They furnish, at best, a rough road map of a very
difficult biological terrain and without providing navigation
for the journey itself.
This leaves unanswered, as all guidelines must by their
very nature, the nagging question, “Who is uncovered?” Sev-
eral groups suggest themselves: infants of gestational age or
birth weight just above the boundary set in the guidelines. After
all how much different is a 33 week premature or 1255 g in-
fant from one just under those boundaries? Others that come
to mind are infants outside the guidelines with severe pulmo-
nary/cardiac disease, severe intracranial hemorrhage, infants
who have undergone major surgical procedures, are the prod-
uct of artificial insemination, genetic disease, or blood loss.
These are handled today very much on an ad hoc basis. Can
we do better? In what follows I would like to make the case
that not only can we, but we must.
Modern neonatology is among the most advanced medi-
cal specialties. A victim of its own success, that success is
being exported over the globe to developing nations and al-
ready developed nations. Smaller and gestationally younger
infants are being saved in numbers never before experienced.
The result is predictable and is being witnessed in nurseries
every day. Where good neonatology is in place more 400-500
g, 23-25 week infants are surviving. Ophthalmologists are di-
agnosing zone I and rush disease ROP [97,185] more frequently
than ever before. Resources and manpower necessary to con-
tinue such tight surveillance are limited. The safety net is
frayed, even in this country for reasons we do not need to
discuss. We must, for these two very practical reasons, think
anew and act anew. We cannot escape this wave of premature
infants alive and vulnerable to this scourge of blindness.
What can we do? Consider that in a year a well-trained
pediatric ophthalmologist is responsible for the care of 100
premature infants of <1250 g birth weight and/or 28 weeks
gestational age in a level 3 nursery. She performs an average
of 5 exams on each infant or a total of 500 exams annually.
This is all she can spare from her busy practice and takes her
in excess of a half day/week. Of these infants, 40-50 will have
ROP, 10 will have stage 3, and 3-5 will require laser therapy.
She is obviously performing her professional duty well within
the current guidelines and is stretched to the limit to do so.
Now consider another scenario. At her office computer
she examines the high quality digital images of the 100 infant’s
retinas taken by a well trained neonatal nurse. She determines
that 60 need only be seen in her office following discharge for
routine examinations. For 40, she wants the nurse to take a
second image in 1-2 weeks. She satisfies herself that 30 need
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only routine office follow up, 10 need her examination and
diagnostic skills, and 5 require her superb laser technique. With
the time saved, she can extend her highest quality to perhaps
ten nurseries considerably extending the radius of her exper-
tise. In so doing, she works closely with the ophthalmologists,
neonatalogists, and neonatal nurses to bring these units up to
the level of her own, thereby providing the best service pos-
sible for these infants.
Can we make it better? What if we were to perfect the
software, the network links, the camera (a huge problem at
present), and the service and support necessary to maintain
such a system? What would it look like? Figure 12 is a sche-
matic showing the potential of such a system to accomplish
our sought after goal. Do not be fooled by the seeming sim-
plicity of the network. The devil, as always, resides in the
details. We at Columbia are focused on three aspects today:
the necessary training and testing of reading center personnel,
camera development, and the development and testing of the
informatics infrastructure necessary to make the network op-
erate seamlessly.
What sort of product might we be looking at? Figure 13,
Figure 14, and Figure 15 are examples of the type of high
quality digital images we might be examining. With enhance-
ment, mainly increasing the contrast, subtracting the red fully
and a little blue, we can enhance the vascular architecture with-
out resorting to fluorescein angiography, although this may
once again become the useful research tool it once was in the
past [186,187].
As physicians and ophthalmologists, we are faced with a
worldwide problem of the scourge of this blinding disease,
ROP, not because of any medical error as in the epidemic of
the 1940s and 1950s, but because of the spread of the scien-
tific knowledge underlying the success of the worldwide ap-
plication of the principles of modern neonatology. We cannot
turn our back on this challenge. We must think anew and act
anew; we cannot escape the inexorable consequences of medi-
cal progress.
SESSION 3F: RESULTS OF THE EARLY TREATMENT
FOR RETINOPATHY OF PREMATURITY STUDY
Contributors: William Good, Robert Hardy (on behalf of
the Early Treatment for Retinopathy of Prematurity Co-
operative Group)
ROP is one of the most widely and thoroughly studied
diseases in pediatric ophthalmology, yet it continues to be a
major disability occurring in preterm infants [188,189], and is
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Figure 14. Digital fluores-
cein angiogram of ROP.
Fundus photograph (top
left) and series of images
from a fluorescein angio-
gram of an ROP subject
with stage 3 ROP.
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one of the most common causes of severe visual impairment
in childhood [190]. Peripheral retinal ablation was shown to
be effective in reducing the incidence of retinal detachment
and blindness in the CRYO-ROP study [99]. Retinal ablation
in the CRYO-ROP study occurred when a prerequisite amount
and severity of ROP was reached (i.e., the threshold for treat-
ment of ROP). In the Early Treatment for Retinopathy of Pre-
maturity study (ETROP), we measured whether earlier treat-
ment of high-risk prethreshold ROP using ablation of the avas-
cular retina results in improved grating visual acuity and reti-
nal structural outcomes compared with conventional treatment.
Methods: Study protocols were approved by the review
boards of all participating institutions, and parents provided
written informed consent prior to infants’ enrollment in the
study and again at randomization. Infants with birth weights
less than 1251 g and birth dates between October 1, 2000, and
September 30, 2002, were screened at 26 participating cen-
ters. Infants who survived at least 28 days underwent serial
eye examinations, with the first screening examination occur-
ring by 42 days after birth. If an infant developed ROP, par-
ents were asked to consent to data collection and a possibly
increased frequency of examinations. Study-certified ophthal-
mologists conducted serial examinations to measure the rate
of progression of ROP, development of prethreshold ROP, and
development of threshold ROP. Infants with retinal vessels
ending in zone I but no ROP or with zone II, stage 2 ROP
received follow-up at least once per week. Infants with zone
II, stage 1 ROP were examined at least every 2 weeks. If at
least one eye reached prethreshold ROP, the infant’s demo-
graphic and ROP information was entered into the RM-ROP2
risk model to determine the likelihood of progression to an
unfavorable outcome in the absence of treatment [103].
Prethreshold was defined as any ROP in zone I, but less than
threshold; or zone II stage 2 or 3 with plus disease (but fewer
than 5 contiguous or 8 cumulative clock hours of stage 3); or
zone II, any amount of stage 3 without plus disease.
If the risk of progression to an unfavorable outcome in
the absence of treatment was calculated to be 15% or higher
and a second examination by a masked study-certified oph-
thalmologist confirmed findings consistent with this risk, con-
sent for the randomized trial was obtained and randomization
occurred. Eyes that had a risk of 15% or higher were termed
high-risk prethreshold. Eyes with less than a 15% risk were
termed low-risk prethreshold and received follow-up exami-
nations every 2 to 4 days for at least 2 weeks, until the ROP
regressed or the risk progressed to 15% or higher.
Infants with bilateral high-risk prethreshold ROP (n=317)
had one eye randomized to early treatment with the fellow
eye managed conventionally (control eye). In asymmetric cases
(n=84), the eye with high-risk prethreshold ROP was random-
ized to early treatment or conventional management. High risk
was determined using a model based on the CRYO-ROP natu-
ral history cohort [103]. At a corrected age of 9 months, masked
testers using the Teller acuity card procedure assessed visual
acuity. At corrected ages of 6 and 9 months, eyes were exam-
ined for structural outcome. Outcomes for the 2 treatment
groups of eyes were compared using χ2 analysis, combining
data for bilateral and asymmetric cases.
Results: Results from the 366 infants with follow up are
shown in Table 7 and Table 8. Grating acuity results showed a
reduction in unfavorable visual acuity outcomes with earlier
treatment, from 19.5% to 14.5% (p=0.01). Unfavorable struc-
tural outcomes were reduced from 15.6% to 9.1% (p<0.001)
at 9 months.
Conclusion: The results of this study show that it is pos-
sible to identify characteristics of ROP that predict which eyes
are most likely to benefit from early peripheral retinal abla-
tion. Based on study data, a clinical algorithm was developed
to identify eyes with prethreshold ROP that were at highest
risk for retinal detachment and blindness while minimizing
treatment of prethreshold eyes likely to show spontaneous re-
gression of ROP. The use of this algorithm circumvents the
need for computer-based calculation of low risk or high risk,
as was used in this study. Details of this analysis are published
[185]. The clinical algorithm shows that in most circumstances,
peripheral retinal ablation should be considered for any eye
with “type 1 ROP”: Zone I, any stage ROP with plus disease;
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Figure 15. Digital fundus photographs of ROP.  Digital fundus pho-
tograph (top) of a subject with hemorrhages and severe, zone I plus
disease. The image was enhanced in the bottom photograph by sub-
tracting out the red and blue.
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Zone I, stage 3 ROP with or without plus disease; or Zone II,
stage 2 or 3 ROP with plus disease.
Plus disease, in this instance, requires at least two quad-
rants of dilation and tortuosity of the posterior retinal blood
vessels and, hence, the presence of significant disease. The
algorithm does not take into account all of the other known
risk factors (e.g., extent of stage 3 or birth weight), and there-
fore clinical judgment is required in applying this initial step
to the management of ROP. The clinical algorithm also indi-
cates that continued serial examinations as opposed to periph-
eral retinal ablation should be considered for any eye with
“type 2 ROP”: Zone I, stage 1 or 2 ROP without plus disease
or Zone II, stage 3 ROP without plus disease.
Treatment should be considered for an eye with type 2
ROP when progression to type 1 status or threshold ROP oc-
curs. Even with the addition of early treatment for selected
eyes with prethreshold ROP, some eyes will still progress to
an unfavorable visual and/or structural outcome. Thus, addi-
tional research is needed to identify better methods for the
prevention and treatment of severe ROP.
SESSION 4A: FUTURE THERAPIES
Contributors: Gerard Lutty, John Penn
Tony Adamis described VEGF as the Swiss Army knife
of angiogenesis because this vasoactive factor has so many
biological activities including angiogenesis, induction of fen-
estrations, and inflammatory cell chemoattractant. The VEGF
aptamer currently in clinical trials for age-related macular
degeneration (AMD) neutralizes only VEGF164 and the differ-
ent isoforms of VEGF have different biological activities.
Because the aptamer blocks formation of NV but not retinal
vascular development, he concludes that VEGF164 stimulates
formation of neovascularization but not normal development
of the retinal vasculature. Furthermore, VEGF164 knockout
mice do not get neovascularization in the mouse model of OIR.
In this model, the vaso-occlusive process is modulated by leu-
kocytes who have the VEGF receptor FLT-1.
Marty Friedlander has demonstrated that one type of stem
cell, hemangioblasts, will home to retina and its developing
vasculature. Maria Grant has demonstrated that hemangioblasts
will participate in the formation of retinal and choroidal
neovascularization. Friedlander suggested that this could be a
method to delivery genes for therapy to sites of
neovascularization. Friedlander has demonstrated that
hemangioblasts injected into vitreous of neonatal mice orga-
nize on the astrocyte template and contribute to formation of
the retinal vasculature. This appears to be accomplished by R-
cadherin related homing, which he suggested might be a use-
ful target in blocking neovascularization in retina. One ques-
tioner asked if cord blood could be used a source of autolo-
gous hemangioblasts? Although cord blood contains
hemangioblasts, Friedlander said it had not been determined
if these hemangioblasts could be expanded and live long
enough to aid in therapy. Other questions concern how to tar-
get them only to sites in the eye and if these cells from mar-
row actually participate in the normal development of the reti-
nal vasculature.
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TABLE 7. NINE MONTH GRATING ACUITY OUTCOME FOR RANDOMIZED
PATIENTS
              Eyes treated
              at high-risk    Conventionally
              prethreshold     managed eyes
             --------------   --------------
               N      % UF      N      % UF    χ-sq      p
             -----   ------   -----   ------   -----   -----
Bilateral     287     15.7     287     20.9    7.26    0.007
Asymmetric     43      7.0      36      8.3    0.05    0.82
             -----   ------   -----   ------   -----   -----
Total         330     14.5     323     19.5    6.60    0.01
The Grating Acuity assessed with Teller acuity cards was judged as
favorable or unfavorable (UF) in each eye at 9 months corrected age.
The table shows the number of infants (N) categorized into those
who had high risk prethreshold ROP in both eyes (bilateral) or only
in one eye (asymmetric). The χ2 test (χ-sq) for the infants with bilat-
eral ROP was based on pairs for eyes with discordant outcomes (23
infants had an eye treated early with a favorable outcome and an eye
managed conventionally with an unfavorable outcome; 8 infants had
an eye treated early with a unfavorable outcome and an eye managed
conventionally with an favorable outcome). Early treatment signifi-
cantly improved grating visual acuity outcomes.
Republished with permission of the American Medical Asso-
ciation from Early Treatment For Retinopathy Of Prematurity Coop-
erative Group. Revised indications for the treatment of retinopathy
of prematurity: results of the early treatment for retinopathy of pre-
maturity randomized trial. Arch Ophthalmol 2003; 121:1684-94.
Copyright ©2003 American Medical Association. All rights reserved.
TABLE 8. NINE MONTH STRUCTURAL OUTCOME FOR RANDOMIZED
PATIENTS
              Eyes treated
              at high-risk    Conventionally
              prethreshold     managed eyes
             --------------   --------------
               N      % UF      N      % UF    χ-sq       p
             -----   ------   -----   ------   -----   -------
Bilateral     289     10.4     290     17.2    11.7    <0.001
Asymmetric     42      0.0      36      2.8     1.2     0.28
             -----   ------   -----   ------   -----   -------
Total         331      9.1     326     15.6    12.6    <0.001
The analysis was based on the structural outcome of these eyes ob-
served by the examining ophthalmologist at the 9 month examina-
tion and each was classified as favorable or unfavorable (UF). Twenty-
four eyes with partial retinal detachment not including the macula
(stage 4A) had vitrectomy or a scleral buckle procedure prior to the 9
month examination and are included in this table as having an UF
outcome. Stage 4B or 5 eyes were considered UF in this study a
priori. There were 292 patients with bilateral ROP and 43 with asym-
metric ROP. The structural outcome could not be determined for five
of the bilateral eyes, and one of those with asymmetric ROP. The χ2
test (χ-sq) for the infants with bilateral ROP was based on discordant
pairs (25 infants had an eye treated early with a favorable outcome
and an eye managed conventionally with an UF outcome; 6 infants
had an eye treated early with a UF outcome and an eye managed
conventionally with a favorable outcome), and showed a significantly
improved outcome for the early treated eyes (p<0.001).
Republished with permission of the American Medical Asso-
ciation from Early Treatment For Retinopathy Of Prematurity Coop-
erative Group. Revised indications for the treatment of retinopathy
of prematurity: results of the early treatment for retinopathy of pre-
maturity randomized trial. Arch Ophthalmol 2003; 121:1684-94.
Copyright ©2003 American Medical Association. All rights reserved.
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Arup Das has demonstrated that antiprotease strategies
can be used to control the formation of intravitreal
neovascularization in the mouse model of OIR. BB-94 (inhib-
its matrix metalloproteinases [MMPs]), B-428, and A6 (in-
hibits urokinase) significantly inhibit the formation of NV but
do not affect normal development of the retinal vasculature in
mouse. Soluble TEK or TIE-2 receptor inhibits formation of
NV and reduces the production of MMPs.
Maria Grant has developed ribozymes that target recep-
tors important in binding angiogenic growth factors.
Ribozymes are tRNA like molecules that enzymatically de-
stroy specific mRNAs. They can be targeted to mRNAs for
growth factor receptors. She has successfully made ribozymes
that target adenosine receptors, VEGF receptors, and IGF-1
receptors. The ribozymes against the adenosine A2B receptor
and the IGF-1 receptor inhibit neovascularization in the mouse
model of ROP. Although ribozymes are usually delivered to
cells with a viral vector, Dr. Grant has shown that they can
transfect cells in retina when delivered as naked DNA.
Bill Hauswirth has developed many vectors for gene
therapy of retinal degenerations and retinal neovascularization.
He has designed vectors with adeno-associated virus (AAV)
that have the endostatin, pigment epithelial derived factor, and
angiostatin genes that successfully transfect retinal cells and
inhibit angiogenesis in the mouse model of ROP. Transfec-
tion works well in developing tissues but it has been difficult
to target endothelial cells. He is using different promoters to
attempt to target endothelial cells. Although it is dubious that
viral vectors that exist today could be used in premature ba-
bies, future technologies may make this possible.
This session has suggested a panoply of therapeutic agents
and strategies for controlling the proliferative stage of ROP.
The targets included VEGF and IGF-1, their receptors, and
proteases. Delivery could be accomplished by hemangioblasts
that home to neovascularization or molecular vectors that could
degrade growth factor receptors or cause overexpression of
endogenous antiangiogenic agents. Dr. Arnall Patz, to whom
this meeting is dedicated, offers some closing thoughts and
optimism that these new ideas may become viable therapies.
SESSION 4B: ANTI-VEGF STRATEGIES: BIOLOGICAL
SPECIFICITY IS ENCODED IN THE VEGF ISOFORMS
AND THEIR RECEPTORS
Contributors: Anthony Adamis, David Shima
Our appreciation for the biology of VEGF has matured
over the last 20 years to the point where VEGF can now be
considered a “middle aged” growth factor. VEGF was first
identified and partially purified in 1983 by Don Senger in
Harold Dvorak’s laboratory [191]. In its infancy, VEGF was
known as vascular permeability factor (VPF), based on its
potent effects on vascular permeability. In 1989, Leung et al.
[192] at Genentech, and Keck et al. [193] at Monsanto cloned
and characterized VPF’s cDNA. It was also demonstrated that
VPF was an endothelial cell mitogen that promoted angio-
genesis in vivo. VPF was rechristened VEGF, and the latter
term has seen widespread adoption.
With these two new ascribed bioactivities, VEGF was
viewed as a potentially important angiogenic factor and con-
sequently was studied in several ophthalmic models. VEGF
was shown to be produced in ocular tissues [194] and VEGF
levels were demonstrated to rise synchronously and in pro-
portion to the degree of pathological neovascularization in the
nonhuman primate eyes [86]. Similar correlations with patho-
logical neovascularization were seen in fluids sampled from
human eyes at the time of surgery [88,89]. In an adult nonhu-
man primate model, VEGF was shown to be necessary [87]
and sufficient [195] for triggering pathological iris
neovascularization. In the context of OIR, it was demonstrated
that VEGF blockade resulted in suppressed pathological reti-
nal neovascularization [84]. VEGF was also shown to be nec-
essary and sufficient for corneal [196] and choroidal
neovascularization [197]. Taken together, these observations
generated excitement about the potential for using anti-VEGF
strategies in the prevention and treatment of pathological
neovascularization in human ophthalmic diseases.
As VEGF was studied in laboratories worldwide, it be-
came apparent that its biological functions were even more
varied and significant than originally believed. Consequently,
our knowledge of VEGF biology has grown significantly as
the molecule has entered “middle age.” In the last decade, the
important role VEGF plays in both vasculogenesis (the de novo
formation of blood vessels) and angiogenesis (the sprouting
of new vessels from existing ones) has been documented
[198,199]. In addition to these bioactivities, it is now known
that VEGF is a critical survival factor for endothelial cells
[67], provides spatial guidance for vascular sprouts [200], and
is instrumental in the formation and maintenance of fenestrae
(cellular structures found in certain highly specialized normal
tissues such as the choriocapillaris) [201]. VEGF is also a
potent inflammatory cell chemoattractant [202] and a
neuroprotection factor [203]. Due to its ability to perform these
many functions, VEGF has been termed the “Swiss army knife”
of vasoactive factors.
How can one growth factor be responsible for selectively
eliciting such disparate biological responses, as seems to be
the case? The answer may reside in the various VEGF isoforms
and receptors. VEGF (VEGF-A) exists as a single gene with
multiple alternatively spliced transcripts that encode for at least
five distinct protein isoforms, ranging in length from 121 to
206 amino acids [204,205]. Alternative splicing results in
isoforms with varying affinities for heparin, affecting VEGF
tissue distribution following secretion. The domains that pro-
mote binding to charged heparin-like moieties are encoded in
exons 6 and 7. The smallest VEGF isoform (VEGF121 in hu-
mans, VEGF120 in rodents) does not bind heparin to any sig-
nificant degree and is able to diffuse freely. The larger isoforms,
VEGF164 and VEGF188, bind heparin-like moieties with increas-
ing affinity and tend to concentrate on the cell surface and
basement membranes.
Using genetically altered mice that expressed a single
VEGF isoform, Shima’s laboratory evaluated the role of the
heparin-binding properties of different VEGF isoforms on the
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branching morphology of blood vessels in the brain [200,206].
Compared to wild-type mice, mice expressing only VEGF120,
a non-heparin binding isoform, had fewer branches at the cap-
illary level in the CNS. In contrast, when mice that were engi-
neered to express only VEGF188, a heparin-binding isoform,
capillary hyper-branching was observed.
VEGF is required for both physiological and pathologi-
cal blood vessel growth, although these vessels differ both
anatomically and physiologically. This paradox was demon-
strated in the neonatal models of OIR. These models expose
neonatal animals to a hyperoxic environment, followed by an
environment of relative hypoxia, to produce pathological reti-
nal neovascularization characterized by tufts of new vessels
that break through the internal limiting membrane. The mod-
els also exhibit physiological neovascularization when the is-
chemic retinal parenchyma is revascularized upon exposure
to room air. As rodent eye development progresses postna-
tally, formation of the normal and pathological retinal vascu-
lature can be followed relatively easily in this species. The
roles of specific VEGF isoforms were evaluated using the
above models and a technique which detects the presence of
leukocytes in the retinal vasculature [73]. Normal retinal ves-
sel development in animals exposed to room air alone was
studied in parallel. It was observed that many leukocytes are
present at the leading edge of pathological, but not physiologi-
cal, neovascularization. When absolute VEGF protein levels
also were measured, a modest increase in the overall VEGF
levels during both normal retinal development and prolifera-
tive retinopathy was found. A more striking change was dem-
onstrated in the relative expression of different isoforms. While
VEGF120 and VEGF164 were expressed similarly during physi-
ological neovascularization, the expression of VEGF164 pre-
dominated during pathological neovascularization [73]. This
is consistent with previous work in which it was demonstrated
that VEGF164 is pro-inflammatory when injected into the vit-
reous, triggering the sticking of leukocytes throughout the reti-
nal microvasculature [207].
To confirm that VEGF164 is preferentially involved in the
model of pathological neovascularization, we used an anti-
VEGF aptamer now in development for the treatment of age-
related macular degeneration and diabetic macular edema
[208]. Aptamers, a new class of therapeutics, maintain a highly
specific three-dimensional conformation that allows binding
to a molecular target in a manner similar to the binding of
antibody to antigen. The aptamer (pegaptanib; Macugen™;
OSI Eyetech Pharmaceuticals, Lexington, MA) binds very spe-
cifically to VEGF164 (VEGF165 in humans) and neutralizes the
isoform’s ability to bind to its cognate receptors VEGFR-1
and VEGFR-2. We compared the effects of administration of
pegaptanib with administration of a soluble fusion protein of
VEGFR-1/Fc that blocks the activity of all VEGF isoforms in
the proliferative retinopathy model [73]. Blocking VEGF165
with pegaptanib was as effective as blocking all the isoforms
in preventing pathological neovascularization. When we
treated rodents that were undergoing physiological
revascularization of the retinal parenchyma that occurs in this
model (i.e., in which vessels do not penetrate the internal lim-
iting membrane), pegaptanib had no effect. In contrast, pan-
isoform blockade with VEGFR-1/Fc inhibited physiological
vessel growth. These data suggested that targeting VEGF164
selectively inhibits the pathological vessels but spares the nor-
mal vessels during the revascularization phase.
Additional data in isoform-specific knockout mice sup-
ported the conclusion that VEGF164 plays a key role in patho-
logical neovascularization. When withdrawn from a hyperoxic
environment, neonatal mice lacking VEGF164 expression (but
retaining expression of the VEGF120 and VEGF188) did not de-
velop pathological neovascularization while the wild-type mice
developed proliferative retinopathy [73]. On examination of
the retinas of the VEGF164 null mice, no tufts breaking through
the internal limiting membrane were observed and physiologi-
cal retinal vascular development occurred quite normally.
Therefore, experiments with VEGF164 knockout mice and those
using aptamers to block VEGF164 resulted in the same conclu-
sion; VEGF164 is the predominant isoform responsible for
pathological but not physiological neovascularization.
While these findings show that variations in isoform ex-
pression are important determinants of VEGF biological ac-
tivity, the distribution and activity of VEGF receptors also have
been shown to confer specificity. Among the various VEGF
receptors, the major endothelial cell receptors are VEGFR-1
(also known as Flt-1) and VEGFR-2 (also known as KDR in
the human with Flk-1 being the murine homolog). Interest-
ingly, while knocking out either KDR or Flt-1 was lethal, in-
activation of just the receptor signal transducing domain for
Flt-1 allowed for normal development and angiogenesis [209].
It has been suggested that, at least on endothelial cells, soluble
Flt-1 may serve as a competitor for VEGF binding to VEGFR-
2, thereby controlling VEGF levels in the microenvironment.
The specific roles of VEGF receptors in retinal develop-
ment in neonatal mice and the OIR model was further ex-
plored by Lois Smith’s group. The VEGFR-1-specific ligand,
human placental growth factor-1 (PlGF-1), and the VEGFR-
2-specific ligand VEGF-E, were used to delineate the specific
functions of the two VEGF receptors [91]. VEGFR-1 (Flt-1)
was found to be preferentially expressed in retinal vessels early
in development and its expression greatly increased during
normal retinal vascularization. VEGFR-2 was detected pri-
marily outside the vasculature in the neural retina (this is con-
sistent with a growing body of evidence supporting the im-
portance of VEGF in neuroprotection) and its levels did not
change during normal vascularization. PlGF-1 was able to
block hyperoxia-induced vaso-obliteration, whereas VEGF-
E had no effect on blood vessel survival. These studies sup-
port the notion that variability in the expression and location
of VEGF receptors, in addition to the previously described
variability in VEGF isoforms, are important determinants of
VEGF biology.
The role of leukocytes in vaso-obliteration and vascular
remodeling has been a subject of recent interest. Using rodent
models, we identified a temporal association between the ar-
rival of leukocytes and a reduction in vascular density during
oxygen-induced vaso-obliteration [210]. When leukocytes are
inhibited by specifically deleting the CD18 receptor (a cell
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adhesion receptor found on certain leukocytes for binding to
vasculature) in mice, vaso-obliteration can be reduced. Simi-
larly, rats treated with antibodies that blocked CD18 had sig-
nificantly less vaso-obliteration than did wild-type animals or
those treated with control antibodies. Perhaps there is a way
to combine these findings into a unified hypothesis of the role
for VEGF in vaso-obliteration, as certain leukocyte cell popu-
lations possess functional VEGFR-1 and migrate in response
to VEGF164 via VEGFR-1. The migration of leukocytes is less
robust in response to VEGF120. Blocking VEGFR-1 eliminates
the migration of leukocytes in response to VEGF. We hypoth-
esize that VEGFR-1 prevents vaso-obliteration via a mecha-
nism that involves leukocyte sourced VEGF, as VEGF is
known to be made in many leukocyte populations. Those same
leukocytes (and their VEGF) can then aid and abet the patho-
logical neovascularization process.
In conclusion, since the bioactivities of VEGF span nu-
merous critical functions, pan-VEGF blockade is more likely
to produce unwanted biological effects. The selective target-
ing of specific VEGF isoforms and/or receptors may there-
fore be important in the future treatment of pathological
neovascularization.
SESSION 4C: “STEMMING” VISION LOSS WITH STEM
CELLS
Contributors: Martin Friedlander
Neovascular eye diseases are the most common causes of
vision loss in industrialized nations and represent significant
unsolved medical needs today. While most of these diseases
involve abnormal new blood vessel growth inside the eye, there
are also diseases involving periorbital/ocular proliferation of
blood vessels. Hemangiomas are benign, local growths of pro-
liferating endothelial cells that can expand quite rapidly and
locally invade tissues and vital organs in the head and neck
region of young children. Since the natural history of these
tumors involves proliferative, plateau, and involutional phases,
studying these tumors can teach us about factors that regulate
the normal and abnormal growth of the vasculature. At the
other end of the aging spectrum is age-related macular degen-
eration; this is the leading cause of vision loss in elderly Ameri-
cans, affecting 15 to 20 million people in this country. Ap-
proximately 10-15% of these patients have new blood vessels
growing under the retina secondary to the disease. Finally, the
leading cause of visual loss of Americans under the age of 55
is diabetes; 16-18% of Americans are diabetic and virtually
every one of them will have some form of retinopathy from
the disease after 20 years. I mention diabetes because it is a
member of a broader class of diseases called the ischemic re-
tinopathies, which of course, includes ROP. In all, we are talk-
ing about millions of individuals in this country that suffer
visual loss secondary to the growth of abnormal new blood
vessels. As mentioned at this symposium, ROP can be thought
of as an ischemic retinopathy. Again, it is important to remem-
ber that patients with ischemic retinopathies are usually is-
chemic; the reason children with ROP are making new blood
vessels is because there is inadequate oxygenation at the reti-
nal periphery due to developmental arrest secondary to high
oxygen which we need to give these children because their
lungs are immature when they come out of the maternal “in-
cubator.”
The paradigm of the current therapeutic approach is what
I call “slash and burn;” we sacrifice peripheral retina in an
attempt to match supply to demand thereby protecting central
vision. All of us in the clinics have taken lasers and cryoprobes
to the eyes of these patients in an attempt to decrease meta-
bolic demand in the retina by destroying tissue. Lasers are
destructive treatments. The other obvious consideration is that
tissues in patients with “ischemic retinopathies” are ischemic
and rather than destroying the aberrant vessels, we probably
should think of ways to normalize and maintain them. I would
like to propose a new therapeutic paradigm: rather than inhib-
iting neovascularization and preventing growth of new blood
vessels we should think about encouraging these immature
vessels to mature and let them do what the body is trying to
do, to bring an adequate blood supply.
Based on recent work from our laboratory and prelimi-
nary basic work by many others, we have found that adult
bone marrow contains a population of cells that will target to
sites of neovascularization in the eye and exert profound
vasculo- and neurotrophic rescue effects [211,212]. From pre-
sentations at this symposium, it is apparent that ROP is not
simply a disease of abnormal proliferation and ischemic
nonperfusion but something that profoundly affects the neu-
ral components of the retina, too.
So what is the stem cell [213-220]? Our colleagues in
hematology and stem cell biology define them as pluripotent
cells capable of differentiating into a variety of cell types. They
possess the ability to indefinitely self renew, can generate
multiple cell types in tissues in which they reside, and can
undergo transdifferentiation events. Many of our colleagues
in ophthalmology and vision science have made interesting
and exciting contributions to this field [221-225]. There are
several kinds of stem cells: corneal limbal stem cells; neuro-
retinal stem cells, which under appropriate conditions can be
stimulated to become the adult cells useful for arresting a cer-
tain number of pathologies; retinal and iris pigment epithelial
cells which under certain conditions have been shown to dif-
ferentiate into neuronal cells; and, finally, there is the class of
cells called hematopoietic stem cells (HSC). It is the hemato-
poietic stem cells that I will focus on.
HSC reside in our bone marrow and core blood and can
differentiate into what we call lineage-positive or lineage-nega-
tive cells. By lineage, we refer to their ability to become the
formed elements of blood. Thus, lineage-positive HSC con-
tain cells that, under appropriate circumstances, can differen-
tiate into blood cells such as monocytes, neutrophils, plate-
lets, and red blood cells. The cells we are more interested in
are the lineage-negative cells, which include a fraction of cells
called endothelial progenitor cells (EPC) [226]. These cells
can become mature endothelial cells. They reside in the bone
marrow and under appropriate conditions can be mobilized
into peripheral circulation by a variety of compounds. We know
they participate in postnatal angiogenesis in a variety of sites
in the body, but their precise phenotypic characterization re-
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mains elusive. There are two ways of looking at these stem
cells. One is that they are indigenous bone marrow-derived
stem cells, which under appropriate circumstances are mobi-
lized from the bone marrow, spill into circulation, and target
sites of neovascularization where they can participate in vas-
cular pathology. Our colleagues in other fields have taken ad-
vantage of this phenomenon and use them to target sites of
vascular collateralization. For example, in cardiology we know
that there is a population of these cells which can be mobi-
lized from the bone marrow to target ischemic hearts and pe-
ripheral vessels where they can help collateralize ischemic tis-
sue. In fact, these circulating EPC can be used as surrogate
markers for determining ones ability to recover from ischemic
damage to the heart [227]. Our colleagues in neurology have
demonstrated there are a number of these cells which, under
appropriate circumstances, can be targeted to and differenti-
ate into neural stem precursor cells, suggesting that these cells
have potential to treat a variety of neurodegenerative diseases.
Finally, recent data from several people including Maria Grant
in Gainesville, Scott Cousin in Miami and Karl Csaky from
the NEI, have demonstrated in mouse models of neovascular
eye disease that bone marrow mobilized EPCs can participate
in the abnormal development of choroidal and retinal
neovascular membranes [228,229]. This suggests that in cer-
tain neovascular eye diseases, we may want to think about
blocking the targeting of these bone marrow mobilized stem
cells to sites of abnormal angiogenesis in the retina [230]. This,
however, is not what I will be talking about. Instead, I would
like to focus on the potential use of these cells in a form of
cell-based therapy that targets drugs or trophic molecules to
sites of retinal vascular and neuronal degenerative disease.
Mononuclear cells are obtained from the bone marrow of
adult mice transgenic for green fluorescent protein (GFP) so
that all of the cells obtained are expressing GFP behind the
actin promoter. We then use magnetic beads loaded with anti-
bodies to a variety of lineage markers to separate the lineage-
positive from the lineage-negative fraction; it is the latter, nega-
tive fraction that is enriched for endothelial progenitive cells.
These cells can then be injected directly into the vitreous of
newborn mice and assessed by scanning laser confocal mi-
croscopy for their location and physiological effects. One of
the models we use in the laboratory is the newborn mouse; the
mouse is born without a retinal vasculature and in this regard
is somewhat analogous to the beginning of the 3rd trimester
human retina. When you stain these newborn mouse retinas
with a marker of the vascular extracellular matrix, collagen
IV, you note some collagen IV positive structures around the
optic nerve, and within 24 h after birth you can see a network
of vessels forming. By a week postnatally, these vessels have
nearly reached the retinal periphery. At postnatal day 8 (P8),
these vessels branch and dive deep so that if you now look at
a cross section of the retina, you see a superficial retinal vas-
cular layer and a parallel, deep layer of vessels 40 µm from
the superficial. By three weeks, a third, intermediate layer has
formed. The vessels know how to do this because it turns out
when the mouse is born there is already a preformed astro-
cytic template as evidenced by looking at GFAP-GFP
transgenic mice. At birth these mice contain a template of as-
trocytes over which the endothelial cells will migrate and form
the vasculature. How specific is this interaction between mi-
grating endothelial cells and the underlying astrocytes? It turns
out if you take a transgenic mouse in which all the astrocytes
are green and inject endothelial progenitor cells from adult
bone marrow of GFP transgenic mice into that mouse’s eye at
P3 or P4 you see that the injected stem cells actually target
and adhere to the astrocytes. This is very much analogous to
what happens with endogenous vascular endothelial cells. Two
weeks later you can find green cells on both the superficial
and deep retinal vascular layers. Some of these cells have
formed patent blood vessels as evidenced by the presence of
previously injected rhodamine dextran. Thus, injecting endot-
helial progenitor cells from adult mouse bone marrow into
neonatal mouse eyes will result in the targeting of these cells
to astrocytes and their incorporation into, or close association
with, developing vasculature [212].
Once we established that these cells can selectively tar-
get activated retinal astrocytes and participate in retinal an-
giogenesis we decided to use them as a form of cell based
therapy to see if we could deliver an angiostatic agent to sites
of abnormal angiogenesis. To do this, we turned to a molecule
we have been working on in the laboratory in collaboration
with Paul Schimmel’s lab at Scripps for the past few years.
Let me briefly review this published work for you [231,232].
It turns out that the fragments of various tRNA synthetases
are potent angiogenic or angiostatic agents; T2TrpRS is a small
carboxy-terminal fragment of tryptophan tRNA synthetase and
is a very potent angiostatic agent. We took that cDNA frag-
ment encoding the protein and engineered the coding region
for a signal sequence in front of the T2 fragment. If this plas-
mid is tranfected into lineage-negative HSC and these cells
are then injected into neonatal mouse retinas, we find that
within a week or two after injection we can detect the synthe-
sis of T2TrpRS as evidenced by western blot analysis with an
antibody specific for the T2TrpRS. We also found that the
presence of the T2TrpRS correlated with a complete inhibi-
tion of the forming deep retinal vascular layer. HSC trans-
fected with control plasmids had no such inhibitory effect.
Thus, we have demonstrated, as a proof of concept, that we
can use EPCs as magic bombs to deliver angiostatic agents to
the back of the eye [212].
Can we use these EPCs to exert some sort of trophic and/
or rescue effect on vasculature or neurons that are destined to
degenerate under a variety of circumstances? For example, in
diseases like ROP or diabetes, if we could somehow stabilize
developing neovasculature and make it form new functional
blood vessels, rather than ones which leak fluid or cause trac-
tion detachments, we might be able to relieve ischemia and
avoid a lot of complications of these terrible diseases. To in-
vestigate that, we turned to a mouse model of retinal degen-
eration called the rd/rd mouse. This mouse, shortly after birth,
undergoes a profound degeneration of the outer nuclear layer
such that by one month postnatally there are no photorecep-
tors in the outer nuclear layer; there is also a profound atrophy
of the inner nuclear layer. Additionally, the deep and interme-
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diate vascular layers undergo a profound degeneration such
that by one month postnatally there are only a few remaining
superficial network vessels and little else. If you examine these
mouse retinas with a confocal microscope z-series, what you
see is both the intermediate and deep vascular complexes be-
come markedly atrophic. If you inject lineage-negative HSC
into one eye of an animal, we observe that at 2 months postna-
tally you have essentially normal looking intermediate and
deep vascular layers. In contrast, a contralateral eye injected
with control cells has typical, profound degeneration. If you
look in cross section, not only are the vessels gone but in the
control eye the inner nuclear layer is markedly atrophic and
the outer nuclear layer is completely gone. In the rescued eye,
we not only rescued the blood vessels but we also rescued the
inner nuclear layer and, to some extent, the outer nuclear layer.
When you look as long as 6 months after injection in the res-
cued eye treated with the EPC-containing lineage-negative
HSC population, we observe a reasonably normal intermedi-
ate layer, and an atrophic, but partially present, deep vascular
layer. We have done electrophysiology on these animals in
collaboration with John Heckenlively and Steve Nusinowitz
from UCLA; while these are not normal ERGs, there is some
electrical activity in response to light stimulation in these res-
cued eyes. We observe the same rescue effects when we take
human adult bone marrow and inject lineage-negative HSC
into SCID mice with the rd/rd genotype. Interestingly, we again
see a similar sort of neurotrophic rescue effect whereas in the
control eyes, there is no outer nuclear layer and an atrophic
inner nuclear layer [211].
Thus, we have demonstrated that bone marrow derived
lineage-negative HSC utilize an established astrocytic tem-
plate in both developing and injury-induced mouse vascula-
ture. These HSC, when they are transduced ex vivo with a
transgene encoding an angiostatic protein like T2TrpRS, can
profoundly inhibit new blood vessel formation without affect-
ing already established blood vessels. Incorporation of endot-
helial progenitor cells into the vasculature, can stabilize de-
generating vessels in mice with retinal degeneration and can
also exert a profound neurotophic affect. I will not go into
detail here, but if you do microarray analysis to compare res-
cued and non-rescued eyes, what we find is a tremendous in-
crease in expression of genes encoding anti-apoptotic proteins
including transcription factors and heat shock proteins. We
think that this is probably the mechanism by which these EPCs
are facilitating rescue.
The potentially exciting fantasy here, as it pertains to treat-
ing ischemic retinopathies such as ROP, is whether we can
use these EPCs to rescue and mature otherwise degenerating
vessels. Can we use these cells to stabilize an ischemic retina
and increase its resistance to degeneration? Can we deliver
factors (e.g., neurotrophic) to enhance this effect? The model
or treatment protocol might be to do an autologous cord blood
or bone marrow transplant into the eye of a child recently di-
agnosed with ROP. Based on the studies I have already dis-
cussed, we might expect these cells to target sites where blood
vessels are forming and if these cells are indeed more resis-
tant to ischemic damage perhaps we would not see the kind of
proliferation or vascular leakage we see in some of these is-
chemic retinopathies. To address this potential treatment op-
portunity, we have been using the mouse OIR model in col-
laboration with Lois Smith’s group at Harvard. Using live,
real-time multiphoton confocal microscopy, we have been able
to observe that these lineage-negative HSC do target to sites
of blood vessels in the mouse model of OIR. This is very pre-
liminary data and we can not yet determine if the rescue effect
will also be observed. We have, however, looked at the effect
of these cells in another model of ischemic retinopathy (ob-
tained from John Heckenlively at UCLA) in which intraretinal
microvascular abnormalities are observed when the very low
density lipoprotein receptor (VLDLR) is knocked out. If you
do rhodamine dextran injection, these vessels leak from the
intraretinal microvascular abnormalities that resemble angi-
omatous proliferations not dissimilar from those abnormali-
ties we observe in humans with chorio-retinal angiomatous
proliferation (CRAP), a special type of age related macular
degeneration. If you inject these lineage-negative HSC into
mice with CRAP or OIR, GFP positive EPCs in green appear
to target sites of neovascularization and incorporate into blood
vessels. Preliminary results from our lab suggest that we may
be able to reverse the VLDLR knockout phenotype by inject-
ing normal EPCs into this mouse.
In summary, these bone marrow-derived endothelial pro-
genitor cells use an established template in mice and can pro-
mote angiogenesis. They can incorporate into vasculature, sta-
bilize degenerating vessels, and stabilize degenerating neu-
ronal cell layers, although not to the same extent. We observed
a significant induction of anti-apoptotic genes which may
mediate the vascular and neuronal rescue. When similar popu-
lations of cells are taken from human bone marrow and in-
jected into mice, identical targeting and rescue activities are
observed. Based on these observations, we suggest a new para-
digm for treating ischemic and degenerative retinopathies in-
volving the use of autologous bone marrow stem cell grafts;
this would avoid many of the problems we see in association
with other forms of gene therapy including lack of an immune
response to injected viral particles. We are currently using such
a cell based approach to deliver a variety of anti-angiogenic
and neurotrophic factors to sites of neovascularization and/or
degeneration in the retina. What we would really like to do, of
course, is to see if we could reconstruct, rather than destroy,
abnormal blood vessels that are the retina’s response to is-
chemia in diseases such as ROP and diabetic retinopathy.
SESSION 4D: INHIBITION OF RETINAL
NEOVASCULARIZATION: ANTI-PROTEINASE STRAT-
EGY
Contributors: Arup Das
I want to thank the organizers of this symposium, espe-
cially Jerry Lutty for inviting me to present at this session. It
is an honor for me to be part of this great event saluting Dr.
Arnall Patz who has been a pioneer in the field of ROP re-
search. I am going to discuss the role of proteinases in retinal
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neovascularization (NV) and the anti-proteinase strategy as
an anti-angiogenic armament in the fight against new vessels
in the retina.
A crucial event during angiogenesis is the invasion and
migration of endothelial cells through the capillary basement
membrane and into the adjacent extracellular matrix (ECM).
This invasive process is tightly coupled to the production and
activity of specific extracellular proteinases including the serine
proteinase urokinase plasminogen activator (uPA) and spe-
cific members of the MMP family [233]. Our lab is actively
involved in investigating this pathway in the angiogenesis
cascade in retina.
Role of proteinases in retinal neovascularization: We in-
vestigated the role of proteinases in retinal neovascularization.
We examined by zymography the expression of these enzymes
in human epiretinal neovascular membranes, obtained surgi-
cally from proliferative diabetic retinopathy patients [234].
Similar neovascular epiretinal membranes also grow in eyes
with ROP. Zymography shows both the high 54 kDa and low
33 kDa molecular weight forms of urokinase are present at
significantly higher levels in diabetic membranes than in nor-
mal donor retinas. Quantification of zymograms showed a 6
fold increase in the high molecular weight form and a 4 fold
increase in the low molecular weight form of uPA. Both the
pro- and active forms of MMP-2 and MMP-9 enzymes were
elevated in the human diabetic epiretinal neovascular mem-
branes [234].
To examine the role of proteinases in animal models, we
used the ROP mouse model [235]. We examined by
zymography the level of proteinases in the retinas of the oxy-
gen-treated animals compared to room-air control animals.
uPA, MMP-2, and MMP-9 are all significantly elevated in the
retinas of animals with retinal NV. This was further confirmed
by RT-PCR analysis showing that mRNAs of these protein-
ases are also elevated [235].
To further investigate the role of the uPA/uPA receptor
(uPAR) system during retinal NV, we examined retinas of mice
with active neovascularization by RT-PCR analysis. Expres-
sion of uPAR mRNA was detected in experimental mice on
day 17 during the active angiogenic period. This was in con-
trast to control mice which demonstrated undetectable uPAR
mRNA. The mRNA of uPAR was significantly upregulated
during retinal angiogenesis [236]. To identify the cell types
responsible for the expression of uPAR in the retina, we per-
formed immunohistochemistry on adjacent sections of retinas
using antibodies for uPAR and with the endothelial cell marker
CD31. The expression of uPAR was restricted to endothelial
cells within the superficial layer of the retina and the
neovascular tufts on the surface of the inner limiting mem-
brane [236].
A balanced interplay of proteinases and proteinase inhibi-
tors (tissue inhibitor of MMP or TIMP), has been implicated
during angiogenesis. Interestingly, message and protein of one
of the subtypes of the endogenous inhibitor, TIMP-2, remained
low and significantly less in animals with retinal NV than in
control animals [237]. There was no significant change in
TIMP-3 message levels in retinal tissues, and TIMP-1 mes-
sage and protein were undetectable. Thus there is suggestion
of a temporal role for MMP-2, MMP-9, MT1-MMP, and
TIMP-2 during retinal angiogenesis in response to hypoxia
[237].
In a different study, we also found that the action of
angiopoietins is mediated through proteinases. RT-PCR analy-
sis of retinas from the ROP model for Ang-2 shows that Ang-
2 is significantly increased in ROP compared to control reti-
nas, with the greatest increase on day 17 (the time of maximal
angiogenic response) [238]. Also, we found that stimulation
of cultured retinal endothelial cells with Ang-1 and Ang-2 ac-
tivates the expression of the proteinase MMP-9 at the protein
and mRNA level [238]. If the Ang-2 expression is inhibited,
there is inhibition of expression of MMP-9. How do we sum-
marize this data? The mature vessel, if destabilized, can either
go in the direction of angiogenesis in the presence of VEGF
or regress in the absence of VEGF. During destabilization,
Ang-2 upregulates the expression of MMP-9; this upregulation
of proteinases in endothelial cells by Ang-2 may be an early
response necessary for cell migration during angiogenesis.
Anti-proteinase approach to retinal neovascularization:
Now that we know that proteinases are upregulated during
retinal NV, we wanted to find out whether the anti-proteinase
strategy can suppress retinal neovascularization. We first tried
a synthetic broad-spectrum MMP inhibitor, BB-94 (British
Biotech, Oxford, UK) [235]. Intraperitoneal injection (IP) of
this MMP inhibitor suppresses the growth of human ovarian
carcinoma xenografts and murine melanoma metastases. IP
injections of the BB-94 drug were given to the murine ROP
model on day 12, 14, and 16. At 1 mg/kg dose, there was 72%
reduction of retinal NV [235]. No obvious toxic effects, in-
flammation, or abnormal development was noted at this dose.
However, at a higher dose of 15 mg/kg, there was 90% reduc-
tion but the dose was toxic.
We then investigated the effect of a uPA inhibitor on reti-
nal NV in the ROP model. B-428 (4-substituted benzo-
thiophene-2-carboxamidine; Eisai Research Institute, Andover,
MA) has been shown to effectively block tumor growth in an
animal model of mammary adenocarcinoma and prostate can-
cer. IP injections of this uPA inhibitor were given to the ROP
model on days 12-16 at different doses. There was about 43-
58% inhibition of retinal NV, and the response was dose-de-
pendent [239]. There was no side effect on normal develop-
ment of the retinal vasculature or neural tissue.
Recently, we investigated the effect of another urokinase
inhibitor, A6 (Angstrom Pharmaceuticals, San Diego, CA),
on retinal NV in the ROP model [236]. A6 is an 8-amino acid
novel peptide derived from the non-receptor binding region
of urokinase that inhibits the interaction of uPA with its recep-
tor, uPAR. A6 showed a dose-dependent inhibition on the ba-
sic fibroblast growth factor-stimulated migration of human
microvascular endothelial cells (HMVECs). As the uPA/uPAR
system is involved in cell migration only, there was no effect
of A6 on proliferation of endothelial cells. A6 has been shown
to inhibit tumor growth and metastasis in breast cancer and
glioblastoma models. There was significant tumor reduction
by treatment with both A6 and Cisplatin. These data suggest
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that the combination of an angiogenesis inhibitor that targets
endothelial cells with a cytotoxic agent may be a useful thera-
peutic approach.
We used the A6 peptide in the mouse ROP model. Differ-
ent doses of A6 were injected IP from day 12 to day 16. A6
was found to be effective in suppressing retinal NV by up to
63%, and the response was dose-dependent [236]. We investi-
gated the role of uPAR in facilitating the formation of new
vessels by comparing the extent of oxygen-induced retinal NV
in normal mice and in uPAR-/- knockout mice. There was al-
most 73% reduction of retinal NV in the uPAR-/- knockout
mice compared with normal mice [236]. The inhibition by A6
is very close to the reduction observed in the uPAR knockout
mice. The loss of uPAR activity and its effect on vasculariza-
tion appeared to be limited to abnormal neovascularization,
but not to the normal development of the retinal vasculature.
Whole mount preparation stained for ADPase activity showed
the same vascular pattern overall in the uPAR knockout mice
and in normal mice. RT-PCR analysis of retinas showed that
there was a 2.3 fold decrease in the level of uPAR mRNA in
the A6 treated animals [236].
Using an anti-angiopoietin approach with the Tek delta
Fc (Amgen Washington, Seattle, WA), a fusion protein con-
sisting of the extracellular domain of the murine Tek receptor
fused to the Fc portion of the murine IgG, yielded interesting
data in terms of Ang-2 and its relation to proteinases. An 87%
inhibition of retinal NV was achieved at the high dose of 80
mg/kg [238]. What was most interesting when we did RT-PCR
analysis for MMP-9 of retinas from animals treated with Tek
delta Fc, MMP-9 was found to be significantly decreased by
80% by inhibition of Ang-2 activity [238]. Thus, our specula-
tion is that Ang-2 probably upregulates the proteinase MMP-
9, which then destabilizes the vessel for angiogenesis.
Conclusions: (1) Proteinases are upregulated during reti-
nal neovascularization. (2) Proteinase inhibitors including
MMP inhibitors and uPA inhibitors can suppress retinal an-
giogenesis. (3) A6, an inhibitor of the uPA/uPAR interaction,
significantly inhibits retinal NV in a ROP model and is a prom-
ising, novel drug. (4) Anti-proteinase strategy may be used in
the treatment of retinal NV in ROP.
SESSION 4E: RIBOZYME-MEDIATED GENE SILENC-
ING IN THE MOUSE MODEL OF OIR
Contributors: Lynn Shaw, Maria Grant
Gene Silencing: Historically, two general methods exist
to assay the function of specific components of complex physi-
ological pathways. The first is the use of transgenic knockout
animals in which the gene coding for a specific intermediate
in the pathway has been inactivated. The second is the use of
conventional drugs that act as either antagonists or agonists to
a specific component of the pathway. The production of knock-
out animals is expensive, labor-intensive and can result in em-
bryonic lethality; while conventional drugs have the potential
disadvantage of unwanted side effects due to direct interac-
tion with other components of the same or different pathways
that can make the interpretation of any results problematic.
Here we detail the use of a molecular approach to block the
expression of a specific gene product in order to perturb a
pathway. There are several molecular-based methods for this
type of gene silencing. One method is the use of antisense
oligonucleotides, either DNA or RNA based, that bind the
mRNA to block protein expression. We will not go into
antisense technology since there are excellent reviews cover-
ing this subject [240-242]. Another method is a reasonably
new technique called RNA interference (RNAi). This method
involves a small interfering RNA (siRNA) that anneals to a
target mRNA and signals the cleavage of the target through
the action of an enzyme complex inherent to the organism
called the RNA-induced silencing complex (RISC). The de-
velopment of this method for gene silencing is ongoing and is
discussed in a number of relevant papers [243-245]. The third
method uses a class of catalytic RNAs called ribozymes to
cleave the target mRNA and reduce protein expression.
There are several classes of ribozymes and one useful way
of segregating them is based on their requirements for a pro-
tein subunit. Group I introns require a single protein subunit,
in vivo, for splicing [246]. The one known exception to this is
the mitochondrial intron found in the large ribosomal RNA
subunit of Tetrahymena [247-250]. Group II introns require a
complex composed of several small nuclear RNAs (snRNA)
and proteins called the splicesome for the removal of the in-
tron [251]. RNase P, which cleaves the 5'-precursor from im-
mature tRNAs, also requires a single protein subunit [252,253].
For each of these types of ribozymes the protein serves a struc-
tural role while the RNA, either the introns or the tRNA, is the
sole catalytic component. The class of ribozymes that require
no protein subunit consists of hammerhead and hairpin
ribozymes [254-256]. These ribozymes are small, approxi-
mately 30 to 90 nucleotides, and require magnesium for struc-
ture (hairpin and hammerhead) and cleavage (hammerhead)
[257]. We shall limit our discussion of ribozymes to the ham-
merheads since we are using these types of ribozymes to spe-
cifically cleave the mRNAs of components of the
neovascularization pathway in the mouse model of OIR [55].
A number of cell surface receptors have been implicated
in angiogenesis. The adenosine A2B receptor, the insulin-like
growth factor-1 receptor (IGF-1R) and the VEGFR-1 and
VEGFR-2 are the targets of the ribozymes we have developed
and describe here. These receptors are expressed preferentially
on proliferating endothelial cells and these are the cells we
desire to influence when blocking angiogenesis.
Hammerhead ribozymes design and development: Fig-
ure 16 shows the structure of a typical hammerhead ribozyme
that we use in our studies. The ribozyme is 34 nucleotides in
length and is annealed to a 13 nucleotide target. Annealing of
the target to the ribozymes targeting arms creates stems I and
III. The ribozyme in Figure 16 is a 6-4-6-ribozyme where 6-
4-6 refers to the number of base pairs that are present in stems
I-III representing ribozymes that have targeting arms that form
6 base pair stems. The length of the targeting arms affects the
efficiency of the binding of the target and ribozyme. Longer
targeting arms may adversely affect the overall rate of cleav-
age by improving binding to the target and slowing disasso-
ciation of the ribozyme from the cleavage products and re-
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ducing overall catalytic turnover. Shorter targeting arms, while
increasing the release of the ribozyme after cleavage may also
decrease specificity for the target. The 6-4-6-ribozyme design
has proven to be a reasonable compromise. Bases highlighted
in yellow in Figure 16A comprise the required bases of the
catalytic core of the ribozyme. Substitution of any one of these
bases eliminates catalytic activity. As indicated in Figure 16A,
a substitution of an a C for the indicated G produces an inac-
tive version of the ribozyme and allows the study of the
antisense effects of these molecules. While this version will
still anneal to the target it is catalytically inactive. Therefore,
any reduction in expression or function of the target will be
due to antisense inhibition.
The only sequence requirement for the target of a ham-
merhead ribozyme is a NUX (shown in red in Figure 16A),
where N is any base and X cannot be a G. Cleavage occurs
just downstream of the X [258]. Shimayama et al. [259] dem-
onstrated that the most efficient target cite is a GUC and we
have found that a GUC followed by a pyrimidine rather than a
purine increases cleavage efficiency [260-262]. The accessi-
bility of the target site within the mRNA is the most important
aspect of target selection; Fritz et al. [263] detail the methods
required for the selection of target sites. Target accessibility
can be determined by examining the secondary structure and
thermodynamic stability of the target mRNA using the Mfold
program [264,265]. In addition, once potential targets are se-
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Figure 16. Targeted ribozyme expression vectors in an OIR mouse model.  A: Structure of a generic hammerhead ribozyme annealed to its
target. Cleavage occurs just downstream of the target NUX site where N is any base and X is not a G. Bases highlighted in yellow show the
catalytic core. B: HRECs transfected with plasmids expressing ribozymes targeting vascular endothelial growth factor receptors 1 and 2
(VEGFR-1, VEGFR-2) prevent reduction in occludin levels in high glucose (25 mM). C: Intraocular injection of 1 µg of plasmid expressing
green fluorescent protein (GFP) into the oxygen-induced retinopathy (OIR) mouse model on postnatal day 1 results in increasing GFP expres-
sion on postnatal day 12 through 19. D: Cross section of control retina from mouse from the OIR model showing preretinal neovascularization.
E: Cross section of retina from mouse from the OIR model after intraocular injection on postnatal day 1 with a plasmid expressing IGF-1R
ribozyme. Note lack of preretinal neovascularization.     
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lected, then the corresponding ribozyme, with targeting arms,
must also be examined, in silico, to look for any secondary
structures that would interfere with target annealing [263]. In
vitro methods also exist for the determination of accessible
sites on mRNA, but these are time consuming and, ultimately,
may not be any more effective than target evaluation in silico
[263,266]. Another important consideration when choosing
target sites is their uniqueness. It is important that the ribozyme
only cleave the single target for which it is designed. There-
fore, all target sites must be compared against known sequences
by performing a BLAST search against GenBank.
The focus of our work involves designing ribozymes
against wildtype targets. We want to affect expression from
both alleles. Numerous potential NUX targets exist and we
search for the best possible target. In contrast, for the reduc-
tion of expression of a single mutant allele, the selection of a
target site is usually limited to the mutant site itself. Unfortu-
nately, this means that most mutation sites will not allow for
the design of a sufficiently active ribozyme. While there are
potential solutions for this problem, it is probably best not to
use ribozymes to affect a mutant allele. The reduction in ex-
pression from a mutant allele might best be accomplished with
RNAi technology that allows for a wider selection of target
sites than does ribozyme technology.
Once the ribozyme and target site have been selected, the
corresponding RNA oligonucleotides are purchased
(Dharmacon, Boulder, CO) and in vitro multiple turnover ki-
netic analysis is performed to evaluate whether the ribozyme
has enough catalytic activity to pursue it further [263]. Ham-
merhead ribozyme cleavage is treated as pseudo-first order
kinetics and we determine three kinetic parameters for each
ribozyme (V
max
, K
m
, K
cat) [255,267]. Multiple-turnover reac-
tions are performed under two different conditions: 1 mM
MgCl2 at 25 °C with pH 7.4 or 20 mM MgCl2 at 37 °C with
pH 7.4. We have produced ribozymes that vary widely in the
values of their kinetic parameters, but generally, ribozymes
with a K
cat >1.0 min-1 at 20 mM MgCl2 at 37 °C with pH 7.4
will be cloned for further testing in cells and in vivo. Many
expression vectors are available, but we clone our ribozymes
into AAV vectors because of the potential of packaging these
vectors into AAV. However, we have found sufficient expres-
sion of the ribozymes from the plasmids for simple transfec-
tion experiments and for intraocular injections into the OIR
mouse model [263].
Expression of ribozymes in human retinal endothelial
cells: Plasmids expressing ribozymes are used to transfect pri-
mary cultures of human retinal endothelial cells (HRECs). A
number of transfection protocols and reagents are available,
and currently we are using the Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA), as its utilization results in 100%
transfection efficiency in HRECs with almost 100% cell vi-
ability following transfection. To determine if the ribozymes
are actually cleaving the desired target, analysis of ribozyme
activity is performed 72 h after transfection of HRECs. RT-
PCR, or real time RT-PCR, is performed on total RNA or
mRNA to assay levels of the target RNA. Western analysis is
performed to determine if the ribozymes have reduced expres-
sion of the protein product. Generally, significant reduction
of both the RNA and protein has been found, and we have
observed a significant level of reduction in RNA and protein
levels from the antisense binding of the ribozyme to the target
RNA in HRECs. Functional analysis, such as cell migration
assays, can also be performed on the transfected cells.
One of the main justifications for using ribozymes is to
assay for the affect of the reduction in expression of a specific
component of a pathway on other components of that path-
way. Since ribozymes can be designed to only cleave the de-
sired target, any affects on the pathway can be directly attrib-
uted to the reduction in expression of the target protein. One
example of this can be found in tight junctions. Tight junc-
tions form between endothelial cells in order to prevent leak-
age of vascular fluid. In proliferative retinopathies, tight junc-
tion integrity is lost and leakage occurs resulting in hemor-
rhage and detachment. Occludin is a transmembrane protein
integral in the formation of tight junctions. In diabetics, under
conditions of high serum glucose, occludin levels are reduced
and tight junction integrity is lost. In order to examine the role
of VEGF on this process we produced two ribozymes, one
targeted against VEGFR-1 and the second targeted against
VEGFR-2. Our initial results on transfected HRECs demon-
strate that both ribozymes prevent occludin loss under high
glucose conditions suggesting that VEGF reduces tight junc-
tion integrity through both receptor subtypes (Figure 16B).
Intraocular injection of ribozymes into the OIR mouse
model: The ultimate test of a ribozyme is its ability to func-
tion in an in vivo model. We tested our ribozymes in the OIR
mouse model [55]. The short time course of this model is ideal
for quickly assessing the effects of ribozymes on retinal
neovascularization, but it is important to determine the ex-
pression pattern of the ribozymes within this model to make
certain that sufficient expression is occurring during the hy-
poxic stimulation of neovascularization. In addition, it is im-
portant to determine the level of ribozyme expression during
normal vasculature development of the eye. To examine this
issue, we injected plasmids intraocularly that expressed GFP
rather than a ribozyme in order to visually monitor expression
levels in our plasmids. Plasmid was injected intraocularly on
postnatal day 1 and the mice then proceeded through the 17
day OIR model with mice being sacrificed at various times
(days 2 through 19). Retinas were flat mounted and the num-
ber of GFP positive cells per high-power field per retina was
determined. Our results show that expression of GFP is visu-
ally observed on postnatal day 12 and increases through post-
natal day 19 (Figure 16C). Because ocular development is
largely completed by day 12, expression of ribozymes from
our plasmids should not interfere with the normal develop-
ment of the retinal vasculature, and should occur at sufficient
levels during hypoxia-stimulated neovascularization (days 12
through 17). Thus, we are not influencing the vaso-oblitera-
tion phase of the model but we are affecting the
vasoproliferative phase.
Using the OIR mouse model, we examined the affect on
neovascularization of reducing the expression of the adenos-
ine A2B and the IGF-1 receptors. Intraocular injection of the
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plasmid expressing the adenosine A2B receptor ribozyme re-
duced preretinal neovascularization by approximately 53%
while injections with plasmid expressing the IGF-1R reduced
preretinal neovascularization by approximately 65%. Cross
sections of the eyes also demonstrate no unusual structural
changes in eyes injected with ribozyme-expressing plasmids,
supporting the idea that plasmid expression occurred prima-
rily following vascular development and during the onset of
neovascularization. Figure 16D,E shows typical cross sections
of retinas that have undergone the OIR model with and with-
out the injection of a plasmid expressing the IGF-1R ribozyme.
These results demonstrate the validity of using ribozymes to
manipulate a complex physiological pathway like angiogen-
esis.
SESSION 4F: AAV MEDIATED GENE THERAPY
REDUCES RETINAL NEOVASCULARIZATION IN THE
ROP MOUSE
Contributors: William Hauswirth, Kenneth Burns, Wen-
Tao Deng, Brian J. Raisler
In the retina, proper control of angiogenesis, the forma-
tion of new blood vessels from existing vasculature, is essen-
tial to preservation of vision. Pathologic neovascularization
of retinal and choroidal vessels is central to several prevalent
ocular diseases including ROP, proliferative diabetic retinopa-
thy (PDR) and AMD. PDR and AMD are the leading causes
of blindness in developed countries and ROP is the leading
cause of infant blindness. It is the balance between endog-
enous vascular growth factors, such as VEGF [268], and in-
hibitors of angiogenesis, such as PEDF [269], that are vital
for regulation of retinal vascularization. When this balance is
upset, as happens during and after the hyperoxic treatment of
premature infants, pathologic angiogenesis often occurs that
ultimately results in vision loss.
Although a variety of treatments currently exist for pa-
tients with choroidal or retinal neovascularization, all cause
collateral retinal damage and/or provide only a temporary so-
lution. Clearly the need exists for therapies that require mini-
mal surgical manipulation, preserve existing vision, and pro-
vide long-term amelioration for the various forms of
neovascularization. Several potent and well-tolerated in vivo
inhibitors of neovascularization have been identified, includ-
ing PEDF [270], angiostatin [271] or endostatin [272]. Their
effectiveness as anti-neovascular agents has been primarily
validated through protein injection studies in animal models
[273,274], although viral vector delivered cDNA studies have
also recently appeared [275-285].
Results and discussion: In order to fairly assess the util-
ity of gene-based anti-angiogenic therapies it was important
to first determine the optimal promoter construct and intraocu-
lar site of vector administration to use. Our initial assumption
was that the promoter yielding the highest level of vector en-
coded ocular protein would be the most effective for animal
testing. We assayed by ELISA the amount of ocular protein
encoded by each vector in adult mice using each of five dif-
ferent promoters within AAV vectors administered either to
the subretinal or intravitreal space. The promoters were se-
lected based on their ability to restrict expression to different
subsets of retinal cells. Chicken β-actin (CBA) is a ubiquitous
strong promoter composed of a cytomegalovirus (CMV) im-
mediate early enhancer (381 bp) and a CBA promoter-exon1-
intron1 element (1352 bp). The cis-retinaldehyde binding pro-
tein promoter (2265 bp) is a retinal pigment epithelium spe-
cific promoter when administered subretinally in an AAV vec-
tor (A. Timmers and W. Hauswirth, unpublished data). The
mouse rod opsin promoter [286] (372 bp) is photoreceptor
specific. Platelet derived growth factor promoter (1600 bp) is
specific to retinal ganglion cells when delivered intravitreally
in AAV vectors (A. Timmers and W. Hauswirth, unpublished
data), and the CMV promoter (620 bp) like CBA is also rela-
tively ubiquitous in the retina but expresses at lower levels
than CBA [287].
Vectors containing the CBA promoter, injected either
subretinally or intravitreally, yielded the most consistently
robust levels of secreted passenger gene expression. By refer-
ence to available protein therapy data, we estimate that mea-
sured intraocular levels of vector expressed PEDF and
Angiostatin were well above therapeutic thresholds for inhib-
iting retinal neovascularization. The intraocular level of each
encoded protein was unaffected by the site of vector adminis-
tration, perhaps because all three candidate proteins are either
naturally secreted or engineered to be secreted. Given the po-
tential for retinal damage attendant with subretinal injections,
intravitreal administration is concluded to be the preferable
route of vector administration. Previous work has shown that
AAV vectors with the CBA promoter express preferentially
and efficiently in retinal ganglion cells when injected into the
mouse vitreous space [277]. For purposes of maximizing pro-
tein expression in the retina, we therefore conclude that CBA
promoter containing AAV vectors delivered intravitreally are
best suited for therapeutic evaluation in a retinal NV setting.
Finally, we note that passenger gene expression after
intravitreal vector administration was sustained for at least 21
months in the mouse eye.
Retinal neovascularization was induced by a modifica-
tion of the previously described neonatal ischemic mouse pro-
tocol that employs shifts in oxygen tension [55]. Each AAV
vector (0.5 µl, 5x109 vector genomes) was administered at
postnatal day 1 (P1) and retinas analyzed at P17, the age of
maximal retinal neovascularization. Visualization of complete
retinal vessel beds by whole mount FITC dextrin angiogra-
phy [280] demonstrated that uninjected eyes and eyes injected
with AAV-CBA-GFP did not significantly differ from
uninjected eyes; all showed extensive areas of
neovascularization in the retinal periphery with significant
areas of central avascularity. In contrast, eyes treated with any
of the three candidate cDNA vectors exhibited marked reduc-
tion in peripheral neovascularization and relatively normal
central perfusion.
In order to more quantitatively measure the effects of each
vector on retinal neovascularization, direct counting of endot-
helial cells in the preretinal vasculature was carried out as pre-
viously described [280]. We enucleated and fixed both vec-
tor-treated and control eyes from P17 pups for paraffin em-
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bedded sectioning. Samples of eyes of each animal remained
paired throughout the procedure to allow direct comparison
of vector treated eyes with their untreated contralateral con-
trol eyes. Serial sections (5 µm) were made through the entire
eye, and every 30th section was placed on a single slide and
hematoxylin and eosin stained. These representative sections
provide a reliable method for quantitatively assessing, in an
unbiased manner, the total level of retinal neovascularization
in each eye. Individuals masked to the identity of the treat-
ment groups quantified neovascularization by enumerating all
endothelial cell nuclei found in the vitreous space above the
inner limiting membrane. Comparisons were made between
one eye of each animal injected with therapeutic vector and
the contralateral uninjected eye serving as an internal control.
Care was taken to exclude persistent hyaloid vessels from the
analysis by omitting both retinal vascular endothelial cells not
in direct contact with the anterior face of the retina and all
vascular endothelial cells within 1.5 optic nerve diameters of
the optic nerve head.
Eyes injected with vectors containing either the PEDF,
Kingle domains 1-3 of Angiostatin, or Endostatin cDNAs at
P1 had 70-80% fewer aberrant retinal vascular endothelial cells
at P17 compared to contralateral untreated eyes (n=10-11;
p<0.001 for all comparisons; Figure 17). Vehicle-injected eyes
and eyes injected with AAV-CBA-GFP did not significantly
differ from uninjected eyes in this assay (data not shown).
It was somewhat surprising that an apparently therapeu-
tic endpoint could be elicited by AAV vectors during the 17
days of the experiment because ocular expression in adult mice
requires 3-4 weeks to plateau at super therapeutic threshold
levels (data not shown). To experimentally confirm that in-
traocular protein levels of each were above estimated thera-
peutic thresholds, the amount of each vector expressed pro-
tein was determined by ELISA from ocular extracts collected
daily between P1 and P17. In all cases, encoded protein levels
rose above threshold levels within 1 to 3 days after vector
injection and remained there until the end of the experiment
at P17. Therefore, unlike adult mice in which measurable AAV
vector passenger gene expression in the retina requires sev-
eral weeks to reach its sustained maximal level, such early
ocular vector administration resulted in therapeutic levels of
gene expression within days. The fact that many retinal cells
in a P1 mouse retina are still dividing may provide an expla-
nation for the difference between adult and neonatal expres-
sion because AAV vectors express their passenger genes much
more rapidly in dividing cells [288].
In summary, these experiments support the idea that in-
traocular expression of secretable, anti-angiogenic proteins
using AAV vectors provides a viable way to manage retinal
neovascularization. Additionally, this therapeutic approach
may be applicable to human ROP, assuming the duration of
therapy can be controlled.
SESSION 4G: ROP IS STILL A CHALLENGE FOR
CLINICIANS AND RESEARCHERS
Contributors: Arnall Patz
It was a privilege to serve as Honorary Chairman for this
highly productive symposium on ROP. The organizing co-
chairs, Jerry Lutty, Tailoi Chan-Ling, and Dale Phelps pro-
vided leadership and inspiration to all of the participants. I
also want to congratulate the rest of the organizing committee
which included John Flynn, Jan McColm, Earl Palmer, and
William Tasman for their key role. I especially wanted to rec-
ognize Jerry Lutty for his assistance in soliciting financial sup-
port for the meeting and for contributing significantly to and
editing my final remarks.
As Chairman of the Development Committee, I want to
recognize the special contributors to the symposium. The lead-
ership of Alcon and Allergan provided important support along
with Eyetech Pharmaceuticals, Iridex, Biospherix, Mead
Johnson Nutritionals, and Massie Labs. I also want to thank
the Bernadotte Foundation for Children’s Eye Care, whose
funding made it possible for many international scholars to
attend. We also greatly appreciate the special support from
the National Eye Institute (NEI). On behalf of all the organiz-
ers and participants in the symposium, I want to especially
thank the American Academy of Ophthalmology staff for
scheduling the meeting the day prior to the start of the Retina
Sub-Specialty meetings and their cooperation throughout the
meeting. The participants I have spoken with were very ap-
preciative of this meeting serving as a timely and very useful
addition to the previous International Symposia on ROP.
It has been 50 years since the pioneering study of Everett
Kinsey and our initial observations on retrolental fibroplasia.
Cynthia Cole et al. [289] recently pointed out that “neonatal
care providers do not understand how best to use oxygen in
the most vulnerable premature infants despite more than 50
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Figure 17. Effect of anti-angiogenic cDNA vectors in the mouse ROP
model.  Effect of anti-neovascular cDNA containing AAV vectors on
reducing retinal neovascularization in the ROP mouse. Angiogenic
retinal vascular endothelial cells counts at P17 normalized to the con-
trol eye at 100% are shown for pigment epithelium derived growth
factor (PEDF), Kringle domains 1-3 of angiostatin (K13) and
endostatin cDNAs in intravitreally injected AAV vectors. The p val-
ues for comparison of the control and partner treated eyes are shown
at the bottom.
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years of oxygen therapy in neonatal medicine.” A Danish study
this year states that the apparent progress in the fight against
ROP over many years seems to have come to a halt [290].
A recent study in Korea found a 20.7% incidence of ROP
in their study population and that a gestational age of ≤28 weeks
and a birth weight of ≤1000 g were the most significant risk
factors [291]. Additionally, an English study reported a simi-
lar finding for the latter half of the last decade in their popula-
tion [292]. Therefore, the ability to save younger premature
infants and questions about the correct level of oxygen to
maintain these extremely small infants may be factors in ROP
remaining one of the major causes of blindness globally, as
mentioned in Dr. Miller’s comments and demonstrated in Dr.
Tahiia’s report on management of ROP in Indonesia.
The American Printing House for the Blind has recently
collected data concerning the incidence of ROP in twenty states
as part of their program called “Babies Count: The National
Registry for Children with Visual Impairments Birth to 3
Years.” Their goal is to determine the cause of visual impair-
ment in children from all states in the United States, and its
associated territories, within the near future. Current data from
the 20 states suggests that 16% of the 2,152 visually impaired
children surveyed to date have ROP.
From the exciting work presented at this symposium and
the reports on the incidence of ROP in the US and abroad, it is
apparent that research on ROP must continue. It is important
that basic scientific studies as presented in this symposium
continue so we can better understand how retinal vessels de-
velop and are injured in hyperoxia. Furthermore, the mouse
model of OIR has become the gold standard for research on
retinal angiogenesis, so our understanding of retinal angio-
genesis and how to control it will be advanced by the study of
the proliferative stage of ROP in models of ROP. This should
help us target pathologic events in ROP and develop new thera-
pies. It is equally important that clinical trials continue to im-
prove care of children and management of their retinopathy.
Finally, it is important that basic scientists and clinicians share
their ideas and discoveries at forums like this symposium, so
that the rise in incidence of ROP can be addressed and hope-
fully reversed.
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